Giuseppe Remuzzi

Q: What Schools Are Affiliated With Giuseppe Remuzzi

Giuseppe Remuzzi is affiliated with the following schools: Aarhus University, University of Milan, University of Sydney

Giuseppe Remuzzi's AcademicInfluence.com Rankings

Giuseppe Remuzzi

Philosophy

#1537

World Rank

#2774

Historical Rank

Logic

#238

World Rank

#499

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Giuseppe Remuzzi's Degrees

Doctorate Medicine University of Milan
PhD Nephrology University of Milan

Why Is Giuseppe Remuzzi Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Giuseppe Remuzzi's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 (2012) (11746)
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 (2012) (8152)
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 (2012) (7185)
Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 (2018) (5789)
Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 (2015) (5270)
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. (2001) (5071)
Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 (2015) (4436)
Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 (2016) (4388)
Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015 (2016) (4293)
Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 (2020) (4169)
Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013 (2015) (4152)
Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016 (2017) (3330)
Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017 (2018) (3308)
COVID-19 and Italy: what next? (2020) (2521)
Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019 (2020) (2362)
Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 (2020) (2016)
Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 (2017) (1869)
Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 (2020) (1788)
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. (2009) (1786)
Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition (2015) (1618)
von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. (1998) (1596)
Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 (2016) (1580)
Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 (2018) (1515)
Global, regional, and national burden of stroke, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 (2019) (1485)
Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 (2017) (1477)
Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 (2015) (1475)
The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. (2011) (1262)
Pathophysiology of progressive nephropathies. (1998) (1248)
Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 (2015) (1241)
Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. (2013) (1201)
Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010 (2012) (1159)
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. (2009) (1106)
A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. (1996) (1028)
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. (2004) (956)
Delayed graft function in kidney transplantation (2004) (929)
Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. (2010) (880)
Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria (1999) (862)
Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 (2014) (853)
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. (2013) (796)
Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. (2004) (748)
Albuminuria, a Therapeutic Target for Cardiovascular Protection in Type 2 Diabetic Patients With Nephropathy (2004) (746)
Panethnic Differences in Blood Pressure in Europe: A Systematic Review and Meta-Analysis (2016) (723)
Atypical hemolytic-uremic syndrome. (2009) (720)
International Society of Nephrology's 0by25 initiative for acute kidney injury (zero preventable deaths by 2025): a human rights case for nephrology (2015) (717)
How does proteinuria cause progressive renal damage? (2006) (714)
Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. (2006) (711)
Angiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal Disease (2001) (679)
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial (2010) (678)
Understanding the nature of renal disease progression. (1997) (660)
Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. (2011) (645)
Global, regional, and national levels of maternal mortality, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 (2016) (623)
Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. (2006) (599)
Nephropathy in Patients with Type 2 Diabetes (2002) (585)
Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial (2005) (585)
Angiotensin II revisited: new roles in inflammation, immunology and aging (2010) (584)
Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy (2017) (580)
Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015 (2016) (579)
Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. (1983) (573)
Overview of Complement Activation and Regulation (2013) (571)
Progression, remission, regression of chronic renal diseases (2001) (566)
Nitric oxide synthesis by cultured endothelial cells is modulated by flow conditions. (1995) (559)
Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2015: the Global Burden of Disease Study 2015 (2016) (549)
Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017 (2018) (538)
Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial (1998) (537)
Preventing microalbuminuria in type 2 diabetes. (2004) (533)
Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. (2001) (529)
Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019 (2020) (522)
COVID-19 vaccines: where we stand and challenges ahead (2021) (510)
Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the Global Burden of Disease Study 2016 (2017) (495)
Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. (2001) (487)
Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. (2006) (479)
Global and National Burden of Diseases and Injuries Among Children and Adolescents Between 1990 and 2013: Findings From the Global Burden of Disease 2013 Study. (2016) (475)
Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kB-dependent fashion. (1998) (457)
Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015 (2017) (452)
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. (2015) (447)
Disruption of the Ang II type 1 receptor promotes longevity in mice. (2009) (447)
Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). (1998) (447)
Protein overload stimulates RANTES production by proximal tubular cells depending on NF-kappa B activation. (1998) (434)
Pretransplant Infusion of Mesenchymal Stem Cells Prolongs the Survival of a Semiallogeneic Heart Transplant through the Generation of Regulatory T Cells1 (2008) (429)
Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? (1990) (421)
Erythropoietic response and outcomes in kidney disease and type 2 diabetes. (2010) (421)
Thrombomodulin mutations in atypical hemolytic-uremic syndrome. (2009) (420)
The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. (2005) (417)
Platelet dysfunction in renal failure. (2004) (407)
Chronic renal diseases as a public health problem: epidemiology, social, and economic implications. (2005) (407)
Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015 (2016) (394)
Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. (2001) (389)
Immunity, endothelial injury and complement-induced coagulopathy in COVID-19 (2020) (384)
Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. (2003) (379)
Human Bone Marrow Mesenchymal Stem Cells Accelerate Recovery of Acute Renal Injury and Prolong Survival in Mice (2008) (369)
Adriamycin-induced nephrotic syndrome in rats: sequence of pathologic events. (1982) (361)
STEC-HUS, atypical HUS and TTP are all diseases of complement activation (2012) (353)
Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. (2003) (343)
Early experience with dual kidney transplantation in adults using expanded donor criteria. Double Kidney Transplant Group (DKG). (1999) (343)
Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate. (1995) (341)
Cyclosporin-induced endothelial cell injury. (1986) (338)
URAEMIC BLEEDING: ROLE OF ANAEMIA AND BENEFICIAL EFFECT OF RED CELL TRANSFUSIONS (1982) (336)
Mechanisms of Disease: pre-eclampsia (2005) (329)
Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies (2015) (326)
The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. (2001) (323)
Familial haemolytic uraemic syndrome and an MCP mutation (2003) (320)
Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. (2013) (320)
Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial (2017) (317)
Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): a cross-sectional study. (2016) (308)
Insulin-like growth factor-1 sustains stem cell mediated renal repair. (2007) (306)
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. (2007) (305)
Prognosis of untreated patients with idiopathic membranous nephropathy (1993) (303)
Chronic kidney disease (2017) (302)
Transfer of growth factor receptor mRNA via exosomes unravels the regenerative effect of mesenchymal stem cells. (2013) (300)
Sirtuin 3-dependent mitochondrial dynamic improvements protect against acute kidney injury. (2015) (295)
Strategies for making more organs available for transplantation. (2000) (295)
Podocyte number in normotensive type 1 diabetic patients with albuminuria. (2002) (295)
MicroRNAs in kidney physiology and disease (2015) (294)
Five insights from the Global Burden of Disease Study 2019 (2020) (291)
Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. (2003) (285)
HÆMOLYTIC-URÆMIC SYNDROME: DEFICIENCY OF PLASMA FACTOR(S) REGULATING PROSTACYCLIN ACTIVITY? (1978) (282)
Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016 (2017) (280)
Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. (2011) (278)
Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes (1998) (277)
Chronic Renal Diseases: Renoprotective Benefits of ReninAngiotensin System Inhibition (2002) (276)
The RAAS in the pathogenesis and treatment of diabetic nephropathy (2010) (275)
ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. (2005) (275)
Long-term outcome of renal transplantation from older donors. (2006) (274)
A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. (2006) (272)
Clinical practice. Nephropathy in patients with type 2 diabetes. (2002) (270)
Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade (2020) (268)
Rituximab in idiopathic membranous nephropathy. (2012) (268)
Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. (2005) (266)
Angiotensin converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rat. (1990) (264)
The case of complement activation in COVID-19 multiorgan impact (2020) (264)
Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. (2014) (263)
Factor H family proteins: on complement, microbes and human diseases. (2001) (263)
Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. (2005) (256)
In progressive nephropathies, overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation. (1998) (254)
Glomerular Hyperfiltration and Renal Disease Progression in Type 2 Diabetes (2012) (253)
Recognition and management of acute kidney injury in the International Society of Nephrology 0by25 Global Snapshot: a multinational cross-sectional study (2016) (253)
Heterogeneous nature of renal lesions in type II diabetes. (1993) (251)
A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. (1993) (250)
Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins. (1995) (249)
Regulatory T cells and T cell depletion: role of immunosuppressive drugs. (2007) (246)
Tumor necrosis factor induces glomerular damage in the rabbit. (1989) (245)
Enhanced nitric oxide synthesis in uremia: implications for platelet dysfunction and dialysis hypotension. (1993) (238)
Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy. (2015) (237)
Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. (2005) (236)
Alternative Pathway Activation of Complement by Shiga Toxin Promotes Exuberant C3a Formation That Triggers Microvascular Thrombosis (2011) (235)
MYO1E mutations and childhood familial focal segmental glomerulosclerosis. (2011) (229)
Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. (2002) (229)
Fluid shear stress modulates surface expression of adhesion molecules by endothelial cells. (1995) (228)
HUS and TTP: variable expression of a single entity. (1987) (226)
Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial (2013) (225)
Rituximab in idiopathic membranous nephropathy: a one-year prospective study. (2003) (224)
Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. (1993) (223)
Thrombotic Microangiopathy After Kidney Transplantation (2010) (223)
Reduced umbilical and placental vascular prostacyclin in severe pre-eclampsia. (1980) (223)
Interleukin-6 and RANTES in Takayasu arteritis: a guide for therapeutic decisions? (1999) (221)
A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis (2011) (221)
Spectrum of steroid-resistant and congenital nephrotic syndrome in children: the PodoNet registry cohort. (2015) (221)
Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion. (1993) (220)
Mechanisms and treatment of CKD. (2012) (219)
Sodium intake, ACE inhibition, and progression to ESRD. (2012) (218)
Child and Adolescent Health From 1990 to 2015 (2017) (217)
The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. (2014) (217)
Transplant renal artery stenosis. (2004) (214)
Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKD. (2015) (212)
Functional significance of renal prostacyclin and thromboxane A2 production in patients with systemic lupus erythematosus. (1985) (209)
Role of remission clinics in the longitudinal treatment of CKD. (2008) (207)
Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition. (2011) (205)
Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. (2003) (204)
Performance of Different Prediction Equations for Estimating Renal Function in Kidney Transplantation (2004) (203)
Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. (2003) (202)
Protein Overload-Induced NF-κB Activation in Proximal Tubular Cells Requires H2O2 through a PKC-Dependent Pathway (2002) (202)
ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. (2001) (201)
Conjugated estrogens for the management of bleeding associated with renal failure. (1986) (200)
Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study. (2006) (198)
Time to abandon microalbuminuria? (2006) (198)
Functional significance of exaggerated renal thromboxane A2 synthesis induced by cyclosporin A. (1986) (195)
von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. (2002) (192)
Uremic bleeding: closing the circle after 30 years of controversies? (1999) (190)
Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. (2000) (187)
Tubulo-interstitial lesions mediate renal damage in adriamycin glomerulopathy. (1986) (187)
Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression. (1993) (186)
Renal vascular and thrombotic effects of cyclosporine. (1989) (186)
Endothelin mediates the renal vasoconstriction induced by cyclosporine in the rat. (1990) (186)
Nonviral gene delivery to the rat kidney with polyethylenimine. (1997) (182)
Renal progenitors: an evolutionary conserved strategy for kidney regeneration (2013) (182)
Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. (2014) (182)
Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis (2021) (181)
The interactive Factor H–atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models (2007) (180)
Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study. (2006) (179)
In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. (1999) (178)
Renal and systemic nitric oxide synthesis in rats with renal mass reduction. (1997) (177)
How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. (2002) (177)
Rituximab for idiopathic membranous nephropathy (2002) (175)
Life‐Sparing Effect of Human Cord Blood‐Mesenchymal Stem Cells in Experimental Acute Kidney Injury (2010) (175)
Renal progenitor cells contribute to hyperplastic lesions of podocytopathies and crescentic glomerulonephritis. (2009) (174)
Daily renal hypoperfusion induced by cyclosporine in patients with renal transplantation. (1992) (169)
Reduced platelet thromboxane formation in uremia. Evidence for a functional cyclooxygenase defect. (1983) (169)
Increased renal endothelin production in rats with reduced renal mass. (1991) (168)
Rare inherited kidney diseases: challenges, opportunities, and perspectives (2014) (168)
Recellularization of well-preserved acellular kidney scaffold using embryonic stem cells. (2014) (168)
Global Cardiovascular and Renal Outcomes of Reduced GFR. (2017) (167)
Hepatitis C infection and chronic renal diseases. (2009) (166)
Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: role of factor H abnormalities. Italian Registry of Familial and Recurrent Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. (1999) (166)
Endothelin antagonists (1999) (166)
Epstein-Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant. (2000) (164)
In response to protein load podocytes reorganize cytoskeleton and modulate endothelin-1 gene: implication for permselective dysfunction of chronic nephropathies. (2005) (163)
Maintenance Dialysis throughout the World in Years 1990 and 2010. (2015) (163)
Liver-kidney transplantation to cure atypical hemolytic uremic syndrome. (2009) (163)
Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease. (1997) (163)
Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 1: How to measure glomerular filtration rate with iohexol? (2016) (161)
C3 glomerulopathy — understanding a rare complement-driven renal disease (2019) (161)
l-Arginine Depletion in Preeclampsia Orients Nitric Oxide Synthase Toward Oxidant Species (2004) (160)
New therapeutics that antagonize endothelin: promises and frustrations (2002) (158)
Combined kidney and liver transplantation for familial haemolytic uraemic syndrome (2002) (158)
Cyclosporine-induced renal dysfunction in experimental animals and humans. (1991) (157)
Protein traffic activates NF-kB gene signaling and promotes MCP-1-dependent interstitial inflammation. (2000) (157)
In vivo maturation of functional renal organoids formed from embryonic cell suspensions. (2012) (157)
Localization of Mesenchymal Stromal Cells Dictates Their Immune or Proinflammatory Effects in Kidney Transplantation (2012) (157)
Increased glomerular thromboxane synthesis as a possible cause of proteinuria in experimental nephrosis. (1985) (157)
Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial (2004) (155)
Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation (2013) (154)
Precision of plasma clearance of iohexol for estimation of GFR in patients with renal disease. (1998) (153)
BLEEDING IN RENAL FAILURE (1988) (153)
Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. (2007) (152)
Disparities in Chronic Kidney Disease Prevalence among Males and Females in 195 Countries: Analysis of the Global Burden of Disease 2016 Study (2018) (150)
Cellular responses to protein overload: key event in renal disease progression (2004) (149)
Blocking angiotensin II synthesis/activity preserves glomerular nephrin in rats with severe nephrosis. (2001) (148)
Estimated GFR: time for a critical appraisal (2018) (148)
Fluid shear stress modulates von Willebrand factor release from human vascular endothelium. (1997) (148)
Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus (2007) (147)
Angiotensin converting enzyme inhibition improves glomerular size-selectivity in IgA nephropathy. (1991) (146)
Combining an antiproteinuric approach with mycophenolate mofetil fully suppresses progressive nephropathy of experimental animals. (1999) (145)
Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome. (2007) (144)
Pathophysiologic implications of reduced podocyte number in a rat model of progressive glomerular injury. (2006) (143)
Inhibition of the chemokine receptor CXCR2 prevents kidney graft function deterioration due to ischemia/reperfusion. (2005) (143)
Lymphomas occurring late after solid-organ transplantation: Influence of treatment on the clinical outcome (2002) (143)
Transforming growth factor-beta1 is up-regulated by podocytes in response to excess intraglomerular passage of proteins: a central pathway in progressive glomerulosclerosis. (2002) (142)
Thymic recognition of class II major histocompatibility complex allopeptides induces donor-specific unresponsiveness to renal allografts. (1993) (141)
Mycophenolate Mofetil for the Treatment of Takayasu Arteritis: Report of Three Cases (1999) (140)
Eculizumab in a patient with dense-deposit disease. (2012) (140)
The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysis. (2003) (140)
Insulin Resistance and Microalbuminuria (2006) (139)
Sex related differences in glomerular ultrafiltration and proteinuria in Munich-Wistar rats. (1988) (139)
Monocyte chemoattractant protein-1 is excreted in excessive amounts in the urine of patients with lupus nephritis. (1995) (139)
Effect of low‐dose aspirin on fetal and maternal generation of thromboxane by platelets in women at risk for pregnancy‐induced hypertension (1990) (139)
Binding of complement factor H to endothelial cells is mediated by the carboxy-terminal glycosaminoglycan binding site. (2005) (138)
The pathophysiology and management of thrombotic thrombocytopenic purpura (1996) (138)
Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement. (2005) (138)
Effect of angiotensin-converting enzyme inhibition on glomerular basement membrane permeability and distribution of zonula occludens-1 in MWF rats. (2000) (138)
Mechanisms of acquired thymic unresponsiveness to renal allografts. Thymic recognition of immunodominant allo-MHC peptides induces peripheral T cell anergy. (1994) (137)
Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide. (2010) (137)
Treatment of Bleeding in Dialysis Patients (2009) (136)
Prevention of chronic kidney and vascular disease: toward global health equity--the Bellagio 2004 Declaration. (2005) (135)
Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. (2007) (135)
The losartan renal protection study — rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) (2000) (135)
Early-childhood membranous nephropathy due to cationic bovine serum albumin. (2011) (134)
Constitutive expression of endothelin gene in cultured human mesangial cells and its modulation by transforming growth factor-beta, thrombin, and a thromboxane A2 analogue. (1991) (133)
Interleukin-1β and tumor necrosis factor-α induce gene expression and production of leukocyte chemotactic factors, colony-stimulating factors, and interleukin-6 in human mesangial cells (1991) (133)
Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). (1998) (132)
Protein overload induces fractalkine upregulation in proximal tubular cells through nuclear factor kappaB- and p38 mitogen-activated protein kinase-dependent pathways. (2003) (131)
Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. (2007) (130)
The nephropathy of non-insulin-dependent diabetes: predictors of outcome relative to diverse patterns of renal injury. (1998) (130)
Selective impairment of gene expression and assembly of nephrin in human diabetic nephropathy. (2004) (130)
Glomerular Diseases Dependent on Complement Activation, Including Atypical Hemolytic Uremic Syndrome, Membranoproliferative Glomerulonephritis, and C3 Glomerulopathy: Core Curriculum 2015 (2015) (129)
The GFR and GFR decline cannot be accurately estimated in type 2 diabetics. (2013) (129)
Podocytopathies (2020) (129)
Bone marrow-derived mesenchymal stem cells improve islet graft function in diabetic rats. (2009) (129)
Hemolytic Uremic Syndrome: A Fatal Outcome after Kidney and Liver Transplantation Performed to Correct Factor H Gene Mutation (2005) (129)
Chronic allograft nephropathy in the rat is improved by angiotensin II receptor blockade but not by calcium channel antagonism. (1998) (128)
Pathophysiology of proteinuria and its value as an outcome measure in chronic kidney disease (2013) (127)
Timed urine collections are not needed to measure urine protein excretion in clinical practice. (2006) (125)
Challenges to achieving clinical transplantation tolerance. (2001) (125)
Podocyte–actin dynamics in health and disease (2016) (125)
Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes. (2009) (125)
Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials. (2011) (124)
Multipotent Mesenchymal Stromal Cell Therapy and Risk of Malignancies (2013) (124)
Shiga toxin-2 triggers endothelial leukocyte adhesion and transmigration via NF-kappaB dependent up-regulation of IL-8 and MCP-1. (2002) (123)
RISK OF NONMELANOMA SKIN CANCER IN ITALIAN ORGAN TRANSPLANT RECIPIENTS. A REGISTRY-BASED STUDY (2000) (122)
Favorable Long‐Term Outcome after Liver‐Kidney Transplant for Recurrent Hemolytic Uremic Syndrome Associated with a Factor H Mutation (2006) (121)
Kidney graft survival in rats without immunosuppressants after intrathymic glomerular transplantation (1991) (121)
Effect of combining ACE inhibitor and statin in severe experimental nephropathy. (2002) (121)
Hemolytic Uremic Syndrome in Pregnancy and Postpartum. (2017) (120)
Mesenchymal stromal cells in renal transplantation: opportunities and challenges (2016) (120)
The Nrf2 pathway in the progression of renal disease. (2014) (120)
Plasma infusion for hemolytic-uremic syndrome in children: results of a multicenter controlled trial. (1988) (120)
Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. (2004) (119)
ACE inhibition is renoprotective among obese patients with proteinuria. (2011) (119)
Proteinuria should be used as a surrogate in CKD (2012) (119)
Bleeding in renal failure: altered platelet function in chronic uraemia only partially corrected by haemodialysis. (1978) (119)
Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. (2005) (118)
Long-Term Outcome of Steroid-Resistant Nephrotic Syndrome in Children. (2017) (117)
Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes. (1998) (117)
Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). (1997) (117)
Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL. (2006) (116)
Sirolimus therapy to halt the progression of ADPKD. (2010) (116)
ACE inhibition reduces glomerulosclerosis and regenerates glomerular tissue in a model of progressive renal disease. (2006) (116)
Role of endothelium-derived nitric oxide in the bleeding tendency of uremia. (1990) (115)
PROSTACYCLIN-LIKE ACTIVITY AND BLEEDING IN RENAL FAILURE (1977) (115)
Outrageous prices of orphan drugs: a call for collaboration (2018) (114)
Antiproteinuric therapy while preventing the abnormal protein traffic in proximal tubule abrogates protein- and complement-dependent interstitial inflammation in experimental renal disease. (1999) (113)
Mutations in FN1 cause glomerulopathy with fibronectin deposits (2008) (113)
Angiotensin II modulates glomerular capillary permselectivity in rat isolated perfused kidney. (1996) (113)
Efficacy of coupled plasma filtration adsorption (CPFA) in patients with septic shock: A multicenter randomised controlled clinical trial (2014) (113)
Protein overload-induced NF-kappaB activation in proximal tubular cells requires H(2)O(2) through a PKC-dependent pathway. (2002) (113)
Role of Insulin and Atrial Natriuretic Peptide in Sodium Retention in Insulin-Treated IDDM Patients During Isotonic Volume Expansion (1990) (113)
Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. (2015) (112)
Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial. (2012) (112)
Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab (2020) (112)
Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. (2016) (112)
The aggravating mechanisms of aldosterone on kidney fibrosis. (2008) (111)
Renal Dysfunction in the Presence of Normoalbuminuria in Type 2 Diabetes: Results from the DEMAND Study (2011) (111)
Blocking both type A and B endothelin receptors in the kidney attenuates renal injury and prolongs survival in rats with remnant kidney. (1996) (111)
Platelet hyperaggregability and the nephrotic syndrome. (1979) (110)
Endothelins in the control of cardiovascular and renal function (1993) (110)
A developmental approach to the prevention of hypertension and kidney disease: a report from the Low Birth Weight and Nephron Number Working Group (2017) (110)
Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy (2018) (110)
Human amniotic fluid stem cell preconditioning improves their regenerative potential. (2012) (109)
Ameliorating Hypertension and Insulin Resistance in Subjects at Increased Cardiovascular Risk: Effects of Acetyl-l-Carnitine Therapy (2009) (108)
The Impact of Kidney Development on the Life Course: A Consensus Document for Action (2017) (108)
Global, regional, and national progress towards Sustainable Development Goal 3.2 for neonatal and child health: all-cause and cause-specific mortality findings from the Global Burden of Disease Study 2019 (2021) (108)
Translating the basic knowledge of mitochondrial functions to metabolic therapy: role of L-carnitine. (2013) (108)
Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (Gisen) (2000) (108)
Sirolimus Versus Cyclosporine Therapy Increases Circulating Regulatory T Cells, But Does Not Protect Renal Transplant Patients Given Alemtuzumab Induction From Chronic Allograft Injury (2007) (108)
Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura. (2012) (108)
Progressive glomerular injury in the MWF rat is predicted by inborn nephron deficit. (1998) (107)
Successful Liver‐Kidney Transplantation in Two Children With aHUS Caused by a Mutation in Complement Factor H (2007) (106)
Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results. (2004) (106)
Podocyte repopulation contributes to regression of glomerular injury induced by ACE inhibition. (2009) (106)
A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes (2018) (105)
Proximal tubular cells promote fibrogenesis by TGF-beta1-mediated induction of peritubular myofibroblasts. (2002) (105)
Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study (2006) (104)
Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy. (2017) (104)
Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial. (2007) (104)
Shigatoxin-induced endothelin-1 expression in cultured podocytes autocrinally mediates actin remodeling. (2006) (103)
Adaptations and Lessons in the Province of Bergamo (2020) (103)
Human mesenchymal stromal cells transplanted into mice stimulate renal tubular cells and enhance mitochondrial function (2017) (103)
Verotoxin-1-induced up-regulation of adhesive molecules renders microvascular endothelial cells thrombogenic at high shear stress. (2001) (103)
Verotoxin-1 promotes leukocyte adhesion to cultured endothelial cells under physiologic flow conditions. (1995) (102)
Kidney regeneration (2010) (102)
Inhibiting angiotensin-converting enzyme promotes renal repair by limiting progenitor cell proliferation and restoring the glomerular architecture. (2011) (102)
Age-related nephropathy and proteinuria in rats with intact kidneys exposed to diets with different protein content. (1989) (102)
ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy. (1999) (101)
Aspirin prolongs bleeding time in uremia by a mechanism distinct from platelet cyclooxygenase inhibition. (1987) (100)
A Novel Strategy to Enhance Mesenchymal Stem Cell Migration Capacity and Promote Tissue Repair in an Injury Specific Fashion (2013) (100)
Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects. (2013) (99)
Thrombotic thrombocytopenic purpura and related disorders. (1990) (99)
Angiotensin-converting-enzyme inhibition therapy in altitude polycythaemia: a prospective randomised trial (2002) (99)
Taming the chronic kidney disease epidemic: a global view of surveillance efforts. (2014) (99)
Angiotensin converting enzyme insertion/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies. (2008) (99)
Nature and mediators of renal lesions in kidney transplant patients given cyclosporine for more than one year. (1999) (98)
Chronic kidney disease: a research and public health priority. (2012) (98)
Proteinuria and phenotypic change of proximal tubular cells. (2003) (98)
Monogenic diseases that can be cured by liver transplantation. (2013) (98)
Thromboxane synthesis and action within the kidney. (1992) (96)
Platelets: an update on diagnosis and management of thrombocytopenic disorders. (2001) (96)
Recent Progress in the Pathophysiology and Treatment of FSGS Recurrence (2013) (96)
Upregulation of renal and systemic cyclooxygenase-2 in patients with active lupus nephritis. (1998) (95)
Diets for patients with chronic kidney disease, still worth prescribing. (2004) (95)
Treatment of membranous nephropathy: time for a paradigm shift (2017) (95)
A novel atypical hemolytic uremic syndrome-associated hybrid CFHR1/CFH gene encoding a fusion protein that antagonizes factor H-dependent complement regulation. (2015) (94)
Prostacyclin and human foetal circulation. (1979) (94)
C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. (2007) (94)
Adriamycin-induced glomerulosclerosis in the rat. (1986) (94)
Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients (2001) (93)
Present and future drug treatments for chronic kidney diseases: evolving targets in renoprotection (2008) (93)
Rituximab for idiopathic membranous nephropathy: who can benefit? (2006) (93)
Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 2: Why to measure glomerular filtration rate with iohexol? (2016) (93)
Renal Expression of FGF23 in Progressive Renal Disease of Diabetes and the Effect of Ace Inhibitor (2013) (93)
Verotoxin glycolipid receptors determine the localization of microangiopathic process in rabbits given verotoxin-1. (1992) (93)
Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies (2005) (93)
Permselective dysfunction of podocyte-podocyte contact upon angiotensin II unravels the molecular target for renoprotective intervention. (2006) (92)
THE ACUTE EFFECT OF FK506 AND CYCLOSPORINE ON ENDOTHELIAL CELL FUNCTION AND RENAL VASCULAR RESISTANCE (1992) (92)
Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: the data of the meta-analyses. (2005) (92)
Effect of Cyclosporin A on prostacyclin synthesis by vascular tissue. (1983) (92)
Application of newer clearance techniques for the determination of glomerular filtration rate. (1998) (92)
Effect of angiotensin II antagonism on the regression of kidney disease in the rat. (2002) (90)
Imaging of the porous ultrastructure of the glomerular epithelial filtration slit. (2010) (90)
Predicting Cisplatin-Induced Acute Kidney Injury by Urinary Neutrophil Gelatinase-Associated Lipocalin Excretion: A Pilot Prospective Case-Control Study (2010) (90)
ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies1. (2000) (90)
Chronic kidney disease in the global adult HIV-infected population: A systematic review and meta-analysis (2018) (89)
Proteasomal processing of albumin by renal dendritic cells generates antigenic peptides. (2009) (89)
SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy. (2018) (88)
Relation between ADAMTS13 activity and ADAMTS13 antigen levels in healthy donors and patients with thrombotic microangiopathies (TMA) (2006) (88)
MicroRNA-324-3p promotes renal fibrosis and is a target of ACE inhibition. (2012) (87)
Progression of renal injury toward interstitial inflammation and glomerular sclerosis is dependent on abnormal protein filtration. (2015) (87)
Radial artery remodeling in response to shear stress increase within arteriovenous fistula for hemodialysis access. (2003) (86)
Cardiovascular, respiratory, and related disorders: key messages from Disease Control Priorities, 3rd edition (2017) (86)
Abnormal protein traffic through the glomerular barrier induces proximal tubular cell dysfunction and causes renal injury. (1995) (85)
The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin. (1998) (85)
Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies (2009) (85)
Reversible activation defect of the platelet glycoprotein IIb-IIIa complex in patients with uremia. (1993) (85)
Effects of Manidipine and Delapril in Hypertensive Patients With Type 2 Diabetes Mellitus: The Delapril and Manidipine for Nephroprotection in Diabetes (DEMAND) Randomized Clinical Trial (2011) (84)
Renal expression of monocyte chemoattractant protein-1 in lupus autoimmune mice. (1997) (84)
The complement factor H R1210C mutation is associated with atypical hemolytic uremic syndrome. (2008) (84)
Treatment of the hemolytic uremic syndrome with plasma. (1979) (84)
Bindarit retards renal disease and prolongs survival in murine lupus autoimmune disease. (1998) (83)
Renal progenitors derived from human iPSCs engraft and restore function in a mouse model of acute kidney injury (2015) (83)
Drug-Induced Thrombotic Microangiopathy (2001) (83)
Influence of Co‐Medication with Sirolimus or Cyclosporine on Mycophenolic Acid Pharmacokinetics in Kidney Transplantation (2005) (83)
Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial (2011) (83)
Mesenchymal stem cell therapy promotes renal repair by limiting glomerular podocyte and progenitor cell dysfunction in adriamycin-induced nephropathy. (2012) (82)
Effect of acetate, bicarbonate dialysis, and acetate-free biofiltration on nitric oxide synthesis: implications for dialysis hypotension. (1998) (82)
Renoprotective effect of contemporary blocking of angiotensin II and endothelin-1 in rats with membranous nephropathy. (1998) (82)
Nephropathy of type 1 and type 2 diabetes: diverse pathophysiology, same treatment? (2000) (81)
Pancreas and kidney/pancreas transplants: experimental medicine or real improvement? (1994) (81)
Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-gamma agonist: molecular mechanism of the antiproteinuric effect of pioglitazone. (2006) (81)
Pathophysiologic implications of proteinuria in a rat model of progressive glomerular injury. (1992) (80)
The renoprotective properties of angiotensin-converting enzyme inhibitors in a chronic model of membranous nephropathy are solely due to the inhibition of angiotensin II: evidence based on comparative studies with a receptor antagonist. (1997) (80)
Cardiovascular risk assessment in low-resource settings: a consensus document of the European Society of Hypertension Working Group on Hypertension and Cardiovascular Risk in Low Resource Settings (2014) (79)
Nephrotoxic aspects of cyclosporine. (2004) (79)
ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy. (2008) (79)
Rationale and Trial Design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence of Renal Events (BEACON) (2013) (79)
Measurable urinary albumin predicts cardiovascular risk among normoalbuminuric patients with type 2 diabetes. (2012) (79)
Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease. (2006) (78)
Rosuvastatin treatment prevents progressive kidney inflammation and fibrosis in stroke-prone rats. (2007) (78)
Magnetic resonance imaging biomarkers for chronic kidney disease: a position paper from the European Cooperation in Science and Technology Action PARENCHIMA (2018) (78)
Advancement of mesenchymal stem cell therapy in solid organ transplantation (MISOT). (2010) (78)
Effective CKD care in European countries: challenges and opportunities for health policy. (2015) (78)
The renal toxicity of sustained glomerular protein traffic. (1995) (77)
Thymic Dendritic Cells Express Inducible Nitric Oxide Synthase and Generate Nitric Oxide in Response to Self- and Alloantigens1 (2000) (77)
The hemolytic uremic syndrome. (2005) (77)
Effect of short-term cyclosporine administration in rats on renin-angiotensin and thromboxane A2: possible relevance to the reduction in glomerular filtration rate. (1986) (77)
Validation of a patient-specific hemodynamic computational model for surgical planning of vascular access in hemodialysis patients. (2013) (76)
Plasmapheresis in the treatment of acute renal failure in multiple myeloma. (1979) (76)
Long-term follow-up of recovered patients with COVID-19 (2021) (76)
Mesenchymal Stem Cells in Solid Organ Transplantation (MiSOT) Fourth Meeting: Lessons Learned from First Clinical Trials (2013) (75)
Computational fluid dynamics of a vascular access case for hemodialysis. (2001) (75)
Size regulation of von Willebrand factor-mediated platelet thrombi by ADAMTS13 in flowing blood. (2006) (75)
The Regenerative Potential of Stem Cells in Acute Renal Failure (2006) (75)
Proteinuria predicting outcome in renal disease: nondiabetic nephropathies (REIN). (2004) (74)
CTLA4Ig gene transfer prolongs survival and induces donor-specific tolerance in a rat renal allograft. (2000) (74)
Extracellular vesicles derived from T regulatory cells suppress T cell proliferation and prolong allograft survival (2017) (74)
Successful split liver-kidney transplant for factor H associated hemolytic uremic syndrome. (2009) (74)
Renal injury induced by long-term administration of cyclosporin A to rats. (1987) (73)
Thrombotic thrombocytopenic purpura: evidence that infusion rather than removal of plasma induces remission of the disease. (1993) (73)
Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease (2019) (73)
Evidence that an angiotensin-converting enzyme inhibitor has a different effect on glomerular injury according to the different phase of the disease at which the treatment is started. (1994) (72)
Dose-effect and pharmacokinetics of estrogens given to correct bleeding time in uremia. (1988) (72)
Acute cyclosporine A nephrotoxicity in rats: which role for renin-angiotensin system and glomerular prostaglandins? (1986) (72)
Immunosuppressive treatment for focal segmental glomerulosclerosis in adults. (2008) (72)
Renal function at hospital admission as a prognostic factor in adult hemolytic uremic syndrome. The Italian Registry of Haemolytic Uremic Syndrome. (1992) (72)
Recombinant human erythropoietin to correct uremic bleeding. (1991) (72)
Mesenchymal stromal cells to promote solid organ transplantation tolerance (2013) (72)
Diverse Effects of Increasing Lisinopril Doses on Lipid Abnormalities in Chronic Nephropathies (2003) (71)
Italy's first wave of the COVID-19 pandemic has ended: no excess mortality in May, 2020 (2020) (71)
Propionyl-L-carnitine prevents renal function deterioration due to ischemia/reperfusion. (2002) (71)
MODERATE DOSES OF ASPIRIN AND RISK OF BLEEDING IN RENAL FAILURE (1986) (71)
In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpura (2006) (71)
Nephrotoxicity of increased glomerular protein traffic. (1999) (71)
Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN. (2017) (71)
The global distribution of lymphatic filariasis, 2000–18: a geospatial analysis (2020) (70)
ACE inhibition induces regression of proteinuria and halts progression of renal damage in a genetic model of progressive nephropathy. (1999) (70)
Increased urinary excretion of thromboxane B2 and 2,3-dinor-TxB2 in cyclosporin A nephrotoxicity. (1988) (70)
From Pharmacokinetics to Pharmacogenomics: A New Approach to Tailor Immunosuppressive Therapy (2004) (70)
Screening for complement system abnormalities in patients with atypical hemolytic uremic syndrome. (2007) (70)
Toward MSC in Solid Organ Transplantation: 2008 Position Paper of the MISOT Study Group (2009) (70)
ACE inhibition improves glomerular size selectivity in patients with idiopathic membranous nephropathy and persistent nephrotic syndrome. (2000) (69)
Enhanced proteolysis of plasma von Willebrand factor in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. (1989) (69)
Burden of CKD, proteinuria, and cardiovascular risk among Chinese, Mongolian, and Nepalese participants in the International Society of Nephrology screening programs. (2010) (69)
Prevention programmes of progressive renal disease in developing nations (Review Article) (2006) (69)
ABCB1 genotypes predict cyclosporine-related adverse events and kidney allograft outcome. (2009) (69)
Strategies for national health care systems in emerging countries: the case of screening and prevention of renal disease progression in Bolivia. (2005) (69)
Altered platelet and vascular prostaglandin-generation in patients with renal failure and prolonged bleeding times. (1978) (69)
Hemolytic uremic syndrome: a factor H mutation (E1172Stop) causes defective complement control at the surface of endothelial cells. (2007) (68)
Hemolytic uremic syndrome (2014) (68)
How renal cytokines and growth factors contribute to renal disease progression. (2001) (68)
Early renin‐angiotensin system intervention is more beneficial than late intervention in delaying end‐stage renal disease in patients with type 2 diabetes (2016) (67)
Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy (2014) (67)
Long‐Term Renal Allograft Function on a Tacrolimus‐Based, Pred‐Free Maintenance Immunosuppression Comparing Sirolimus vs. MMF † (2006) (67)
Key fibrogenic mediators: old players. Renin–angiotensin system (2014) (67)
Endothelin induces diuresis and natriuresis in the rat by acting on proximal tubular cells through a mechanism mediated by lipoxygenase products. (1991) (67)
The first clinical and epidemiological programme on renal disease in Bolivia: a model for prevention and early diagnosis of renal diseases in the developing countries. (1998) (67)
Prevalence of Enhanced Granular Expression of Thrombospondin Type-1 Domain-Containing 7A in the Glomeruli of Japanese Patients with Idiopathic Membranous Nephropathy (2015) (66)
A report with consensus statements of the International Society of Nephrology 2004 Consensus Workshop on Prevention of Progression of Renal Disease, Hong Kong, June 29, 2004. (2005) (66)
Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial. (2006) (66)
Membranous nephropathy associated with IgG4-related disease. (2011) (66)
Involvement of renal tubular Toll-like receptor 9 in the development of tubulointerstitial injury in systemic lupus. (2007) (66)
β-arrestin-1 drives endothelin-1-mediated podocyte activation and sustains renal injury. (2014) (66)
Efficacy and Safety of Rituximab Second-Line Therapy for Membranous Nephropathy: A Prospective, Matched-Cohort Study (2011) (66)
Nephropathic nature of proteinuria. (1999) (65)
Organoid Models and Applications in Biomedical Research (2015) (65)
Glomerular filtration rate determined from a single plasma sample after intravenous iohexol injection: is it reliable? (1996) (65)
Blunted excretory response to atrial natriuretic peptide in experimental nephrosis. (1989) (65)
Angiotensin receptors as determinants of life span (2009) (65)
In Kidney Transplant Patients, Alemtuzumab but Not Basiliximab/Low-Dose Rabbit Anti-Thymocyte Globulin Induces B Cell Depletion and Regeneration, Which Associates with a High Incidence of De Novo Donor-Specific Anti-HLA Antibody Development (2013) (65)
Protein Overload Activates Proximal Tubular Cells to Release Vasoactive and Inflammatory Mediators (1999) (65)
Pathophysiology and management of thrombotic microangiopathies. (1998) (64)
Distinct cardiac and renal effects of ETA receptor antagonist and ACE inhibitor in experimental type 2 diabetes. (2011) (64)
Coagulation abnormalities in uremia. (1985) (64)
Subcutaneous desmopressin (DDAVP) shortens the bleeding time in uremia (1989) (64)
Unbalanced prostaglandin synthesis and plasma factors in uraemic bleeding. A hypothesis. (1978) (64)
Thrombotic thrombocytopenic purpura--then and now. (2006) (64)
The role of protein traffic in the progression of renal diseases. (2000) (64)
A COMPARATIVE PROSPECTIVE STUDY OF TWO AVAILABLE SOLUTIONS FOR KIDNEY AND LIVER PRESERVATION (2004) (64)
Prediction of cyclosporine area under the curve using a three-point sampling strategy after Neoral administration. (1997) (63)
Generation of functional podocytes from human induced pluripotent stem cells (2016) (63)
Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). (2009) (63)
Effect of acetate-free biofiltration and bicarbonate hemodialysis on neutrophil activation. (2002) (63)
Whole-blood calcineurin activity is not predicted by cyclosporine blood concentration in renal transplant recipients. (2001) (63)
Radial artery wall shear stress evaluation in patients with arteriovenous fistula for hemodialysis access. (2003) (63)
Hemolytic uremic syndrome (1995) (63)
Measuring and Estimating GFR and Treatment Effect in ADPKD Patients: Results and Implications of a Longitudinal Cohort Study (2012) (62)
Colchicine interferes with L-selectin and leukocyte function-associated antigen-1 expression on human T lymphocytes and inhibits T cell activation. (1996) (62)
Therapeutic Drug Monitoring of Sirolimus: Effect of Concomitant Immunosuppressive Therapy and Optimization of Drug Dosing (2004) (61)
Paricalcitol for secondary hyperparathyroidism in renal transplantation. (2015) (61)
Long-term treatment with either enalapril or nitrendipine stabilizes albuminuria and increases glomerular filtration rate in non-insulin-dependent diabetic patients. (1994) (60)
Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis (2021) (60)
Complement-mediated dysfunction of glomerular filtration barrier accelerates progressive renal injury. (2008) (60)
Nephropathy of type-2 diabetes mellitus. (1998) (60)
Nature and mediators of parietal epithelial cell activation in glomerulonephritides of human and rat. (2013) (60)
Community-based screening for chronic kidney disease, hypertension and diabetes in Dharan. (2013) (59)
Three-dimensional analysis of glomerular morphology in patients with subtotal nephrectomy. (1995) (59)
The renin-angiotensin system in progression, remission and regression of chronic nephropathies. (2002) (59)
Role of increased glomerular protein traffic in the progression of renal failure. (1997) (59)
Proteinuria as a Mediator of Tubulointerstitial Injury (1999) (58)
Measurement of glomerular filtration rate. (1997) (58)
Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathy. (2008) (58)
Time course and localization of endothelin-1 gene expression in a model of renal disease progression. (1997) (58)
Familial Deficiency of a Plasma Factor Stimulating Vascular Prostacyclin (PGI2) Activity (1979) (58)
V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction. (2009) (57)
Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation (2013) (57)
Kidney failure: aims for the next 10 years and barriers to success (2013) (57)
Halting the progression of chronic nephropathy. (2002) (57)
DOPPLER ULTRASONOGRAPHY IN POSTTRANSPLANT RENAL ARTERY STENOSIS: A RELIABLE TOOL FOR ASSESSING EFFECTIVENESS OF REVASCULARIZATION? (2003) (57)
Renal and Systemic Effects of Calorie Restriction in Patients With Type 2 Diabetes With Abdominal Obesity: A Randomized Controlled Trial (2016) (57)
Bleeding in renal failure: is von Willebrand factor implicated? (1977) (56)
Renal progenitors in non-diabetic and diabetic nephropathies (2013) (56)
Worsening kidney function in decompensated heart failure: treat the heart, don't mind the kidney. (2011) (56)
Vasopeptidase inhibitor restores the balance of vasoactive hormones in progressive nephropathy. (2004) (56)
von Willebrand factor cleaving protease ( ADAMTS 13 ) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome (2002) (56)
Is ADAMTS‐13 deficiency specific for thrombotic thrombocytopenic purpura? No (2003) (56)
Cardiovascular complications in atypical haemolytic uraemic syndrome (2014) (56)
Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report. (2005) (56)
Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection. (2010) (55)
Correction of anemia--payoffs and problems. (2006) (55)
Diets for patients with chronic kidney disease, should we reconsider? (2016) (55)
The future of renoprotection: Frustration and promises (2003) (55)
Low-protein diet prevents glomerular damage in adriamycin-treated rats. (1985) (54)
Albuminuria as early test for vascular disease (2005) (54)
Basiliximab. Point of view (1999) (54)
Atrial Natriuretic Peptide and Prostacyclin Synergistically Mediate Hyperfiltration and Hyperperfusion of Diabetic Rats (1992) (54)
Evidence against a pathogenetic role for endothelin in pre‐eclampsia (1992) (54)
Plasma exchange in children with hemolytic-uremic syndrome at risk of poor outcome. (1993) (54)
Sequential monitoring of urine-soluble interleukin 2 receptor and interleukin 6 predicts acute rejection of human renal allografts before clinical or laboratory signs of renal dysfunction. (1997) (54)
Indomethacin reduces proteinuria in passive Heymann nephritis in rats. (1987) (54)
Functional Human Podocytes Generated in Organoids from Amniotic Fluid Stem Cells. (2016) (54)
Pharmacologic control of angiotensin II ameliorates renal disease while reducing renal TGF-beta in experimental mesangioproliferative glomerulonephritis. (1998) (54)
Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019 (2022) (54)
The hemolytic uremic syndromes (2005) (54)
PHARMACOKINETICS OF MYCOPHENOLATE SODIUM AND COMPARISON WITH THE MOFETIL FORMULATION IN KIDNEY TRANSPLANT RECIPIENTS. (2006) (54)
The Toll-IL-1R Member Tir8/SIGIRR Negatively Regulates Adaptive Immunity against Kidney Grafts1 (2009) (53)
Antibody-mediated extraction/negative-ion chemical ionization mass spectrometric measurement of thromboxane B2 and 2,3-dinor-thromboxane B2 in human and rat urine. (1987) (53)
Abnormal permeability to proteins and glomerular lesions: a meta-analysis of experimental and human studies. (1996) (53)
EFFECT OF CYCLOSPORINE ON PROSTACYCLIN SYNTHESIS BY VASCULAR TISSUE IN RABBITS (1983) (53)
Genetic Atypical Hemolytic-Uremic Syndrome (2016) (52)
Bilateral nephrectomy stopped disease progression in plasma-resistant hemolytic uremic syndrome with neurological signs and coma. (1996) (52)
Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies. (2001) (52)
Three-dimensional reconstructed glomerular capillary network: blood flow distribution and local filtration. (1992) (52)
Mapping geographical inequalities in access to drinking water and sanitation facilities in low-income and middle-income countries, 2000–17 (2020) (52)
Experimental Evaluation of Kidney Regeneration by Organ Scaffold Recellularization (2017) (52)
Longitudinal Estimated GFR Trajectories in Patients With and Without Type 2 Diabetes and Nephropathy. (2018) (52)
Glomerular size-selective dysfunction in NIDDM is not ameliorated by ACE inhibition or by calcium channel blockade. (1999) (52)
Genetic analysis of the complement factor H related 5 gene in haemolytic uraemic syndrome. (2007) (51)
Tackling the Shortage of Donor Kidneys: How to Use the Best that We Have (2003) (51)
Shiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complement. (2014) (51)
Proteinuria: Is the ONTARGET renal substudy actually off target? (2009) (51)
Mesenchymal Stem Cells in Kidney Repair. (2016) (51)
PARATHYROID HORMONE INHIBITS HUMAN PLATELET FUNCTION (1981) (51)
Plasmatic regulation of vascular prostacyclin in pregnancy. (1981) (51)
Cigarette smoking and renal function impairment. (1999) (51)
Italy's health performance, 1990–2017: findings from the Global Burden of Disease Study 2017 (2019) (51)
Thrombotic microangiopathy in renal transplantation. (2002) (51)
Prevention and treatment of pregnancy-associated hypertension: what have we learned in the last 10 years? (1991) (51)
MicroRNA-184 is a downstream effector of albuminuria driving renal fibrosis in rats with diabetic nephropathy (2017) (50)
THROMBOTIC TENDENCY IN SYSTEMIC LUPUS ERYTHEMATOSUS (1981) (50)
Increased nitric oxide formation in recurrent thrombotic microangiopathies: a possible mediator of microvascular injury. (1996) (50)
Angiotensin II Blockade Limits Tubular Protein Overreabsorption and the Consequent Upregulation of Endothelin 1 Gene in Experimental Membranous Nephropathy (1998) (50)
Human placenta expresses endothelin gene and corresponding protein is excreted in urine in increasing amounts during normal pregnancy. (1991) (50)
Long-Term Clinical and Immunological Profile of Kidney Transplant Patients Given Mesenchymal Stromal Cell Immunotherapy (2018) (50)
Beneficial Effect of TGFβ Antagonism in Treating Diabetic Nephropathy Depends on When Treatment Is Started (2006) (49)
Cyclin-dependent kinase inhibition limits glomerulonephritis and extends lifespan of mice with systemic lupus. (2007) (49)
Platelet function in patients on maintenance hemodialysis: depressed or enhanced? (1982) (49)
Any value of podocyte B7-1 as a biomarker in human MCD and FSGS? (2016) (49)
Experimental Goodpasture's syndrome in Wistar-Kyoto rats immunized with alpha3 chain of type IV collagen. (1998) (49)
Sirolimus for calcineurin inhibitors in organ transplantation: contra. (2010) (49)
Haemolytic uraemic syndrome: therapeutic effect of plasma infusion. (1982) (49)
Comparison of the effects of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade on the evolution of spontaneous glomerular injury in male MWF/Ztm rats. (1996) (49)
PAF mediates neutrophil adhesion to thrombin or TNF-stimulated endothelial cells under shear stress. (1995) (49)
Progression of chronic kidney disease: insights from animal models (2006) (49)
Direct podocyte damage in the single nephron leads to albuminuria in vivo. (1995) (49)
Prevention and treatment of diabetic retinopathy: evidence from clinical trials and perspectives. (2011) (48)
Diseases of the Kidney and the Urinary System (2006) (48)
Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group. (2020) (48)
INCREASED URINARY EXCRETION OF ENDOTHELIN‐1 AND ITS PRECURSOR, BIG‐ENDOTHELIN-1, IN RATS CHRONICALLY TREATED WITH CYCLOSPORINE (1991) (48)
Increased Fragmentation of von Willebrand Factor, Due to Abnormal Cleavage of the Subunit, Parallels Disease Activity in Recurrent Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura and Discloses Predisposition in Families (1999) (48)
Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial. (2010) (48)
Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis. (2001) (48)
An Ex Vivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome. (2019) (47)
Characterization of a New DGKE Intronic Mutation in Genetically Unsolved Cases of Familial Atypical Hemolytic Uremic Syndrome. (2015) (47)
Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease. (2016) (47)
Interaction between Multimeric von Willebrand Factor and Complement: A Fresh Look to the Pathophysiology of Microvascular Thrombosis (2017) (47)
Changes in glomerular perm-selectivity induced by angiotensin II imply podocyte dysfunction and slit diaphragm protein rearrangement. (2004) (47)
Glomerular response to hyperglycemia in human diabetic nephropathy. (1990) (47)
Sirt3 deficiency shortens lifespan and impairs cardiac mitochondrial function rescued by Opa1 gene transfer. (2019) (47)
Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000–17: analysis for the Global Burden of Disease Study 2017 (2020) (47)
Nitrendipine and enalapril improve albuminuria and glomerular filtration rate in non-insulin dependent diabetes. (1996) (47)
Mapping local patterns of childhood overweight and wasting in low- and middle-income countries between 2000 and 2017 (2020) (47)
Platelet activating factor (PAF) as a mediator of injury in nephrotoxic nephritis. (1987) (47)
Angiotensin-converting enzyme inhibition prevents glomerular-tubule disconnection and atrophy in passive Heymann nephritis, an effect not observed with a calcium antagonist. (2001) (47)
Acute renal failure: an unacceptable death sentence globally (2013) (47)
REDUCTION OF FETAL VASCULAR PROSTACYCLIN ACTIVITY IN PRE-ECLAMPSIA (1980) (46)
Covid-19 and gender: lower rate but same mortality of severe disease in women—an observational study (2021) (46)
Long‐term outcome of renal transplantation from octogenarian donors: A multicenter controlled study (2017) (46)
Physiology and pathophysiology of nitric oxide in chronic renal disease. (1999) (46)
Passive Heymann nephritis: evidence that angiotensin-converting enzyme inhibition reduces proteinuria and retards renal structural injury. (1996) (45)
Renoprotective effect of low iron diet and its consequence on glomerular hemodynamics. (1991) (45)
Clinical Translation of Mesenchymal Stromal Cell Therapies in Nephrology. (2017) (45)
Adult nondiarrhea hemolytic uremic syndrome associated with Shiga toxin Escherichia coli O157:H7 bacteremia and urinary tract infection. (2003) (45)
Two Patients With History of STEC‐HUS, Posttransplant Recurrence and Complement Gene Mutations (2013) (45)
Prevention of Renal Injury in Diabetic MWF Rats by Angiotensin II Antagonism (1998) (45)
Prevention of transplant rejection: current treatment guidelines and future developments. (1997) (45)
Malignant vascular disease of the kidney: nature of the lesions, mediators of disease progression, and the case for bilateral nephrectomy. (1996) (44)
Remission Achieved in Chronic Nephropathy by a Multidrug Approach Targeted at Urinary Protein Excretion (2001) (44)
Biocompatibility and function of microencapsulated pancreatic islets. (2006) (44)
Rare diseases and effective treatments: are we delivering? (2015) (44)
Screening for chronic kidney disease in emerging countries: feasibility and hurdles. (2009) (44)
Rituximab in Primary Membranous Nephropathy: First-Line Therapy, Why Not? (2014) (44)
Bleeding disorders in uremia: pathophysiology and treatment. (1989) (44)
Mapping child growth failure across low- and middle-income countries (2020) (44)
Targeted Downregulation of Extracellular Nephrin in Human IgA Nephropathy (2003) (44)
Peripheral donor leukocytes prolong survival of rat renal allografts. (1999) (44)
ACE inhibition versus angiotensin receptor blockade: which is better for renal and cardiovascular protection? (2004) (44)
Podocyte dysfunction in atypical haemolytic uraemic syndrome (2015) (44)
Ethical issues in dialysis therapy (2017) (44)
The role of chemokines in progressive renal disease. (2009) (43)
Effects of MCP-1 Inhibition by Bindarit Therapy in a Rat Model of Polycystic Kidney Disease (2014) (43)
Antiproteinuric Effect of Chemokine C-C Motif Ligand 2 Inhibition in Subjects with Acute Proliferative Lupus Nephritis (2011) (43)
PROSTACYCLIN GENERATION BY CULTURED ENDOTHELIAL CELLS IN HÆMOLYTIC URÆMIC SYNDROME (1980) (43)
Dendritic Cells Genetically Engineered with Adenoviral Vector Encoding dnIKK2 Induce the Formation of Potent CD4+ T-Regulatory Cells (2005) (43)
Glomerular protein trafficking and progression of renal disease to terminal uremia. (1996) (42)
Protecting single-kidney allografts from long-term functional deterioration. (1998) (42)
Cyclosporine induces glomerulosclerosis: three-dimensional definition of the lesions in a rat model of renal transplant. (1996) (42)
Fractalkine and CX3CR1 Mediate Leukocyte Capture by Endothelium in Response to Shiga Toxin1 (2008) (42)
Variations of the angiotensin II type 1 receptor gene are associated with extreme human longevity (2013) (42)
Prostacyclin and thrombotic microangiopathy. (1980) (42)
Basiliximab combined with low-dose rabbit anti-human thymocyte globulin: a possible further step toward effective and minimally toxic T cell-targeted therapy in kidney transplantation. (2006) (42)
Renal protective effect of angiotensin-converting enzyme inhibition in aging rats. (1992) (42)
Insulin resistance and proliferative retinopathy: a cross-sectional, case-control study in 115 patients with type 2 diabetes. (2004) (41)
Mesenchymal Stromal Cells for Transplant Tolerance (2019) (41)
Angiotensin II contributes to diabetic renal dysfunction in rodents and humans via Notch1/Snail pathway. (2013) (41)
Pharmacokinetics of candesartan cilexetil in patients with renal or hepatic impairment. (1997) (41)
Effect of the Urotensin Receptor Antagonist Palosuran in Hypertensive Patients With Type 2 Diabetic Nephropathy (2010) (41)
Renoprotection by nitric oxide donor and lisinopril in the remnant kidney model. (1999) (41)
Post-transplant Kaposi's sarcoma. (1997) (40)
The effects of AST-120 on chronic kidney disease progression in the United States of America: a post hoc subgroup analysis of randomized controlled trials (2016) (40)
Post-transplant renal artery stenosis: the hemodynamic response to revascularization. (2001) (40)
Glomerular size selectivity in nephrotic rats exposed to diets with different protein content. (1987) (40)
Edema of the nephrotic syndrome: the role of the atrial peptide system. (1993) (40)
Shear stress-induced cytoskeleton rearrangement mediates NF-kappaB-dependent endothelial expression of ICAM-1. (2000) (39)
Thromboxane A2 receptor blocking abrogates donor-specific unresponsiveness to renal allografts induced by thymic recognition of major histocompatibility allopeptides (1994) (39)
Preventing renal and cardiovascular risk by renal function assessment: insights from a cross-sectional study in low-income countries and the USA (2012) (39)
Glomerular perm-selective function. (1994) (39)
Angiotensin-converting enzyme inhibitor therapy for non-diabetic progressive renal disease (1997) (39)
Targeted deletion of angiotensin II type 1A receptor does not protect mice from progressive nephropathy of overload proteinuria. (2004) (39)
Rare diseases: what's next? (2008) (39)
Computed tomography evaluation of autosomal dominant polycystic kidney disease progression: a progress report. (2006) (39)
The role of renin angiotensin system inhibition in kidney repair (2010) (39)
Cellular basis of long-term organ transplant acceptance: pivotal role of intrathymic clonal deletion and thymic dependence of bone marrow microchimerism-associated tolerance. (1998) (39)
Mesenchymal stromal cells for tolerance induction in organ transplantation. (2017) (39)
Structural basis of diabetic nephropathy in microalbuminuric NIDDM patients: a light microscopy study (1996) (39)
Incidence and clinical predictors of Kaposi's sarcoma among 1721 Italian solid organ transplant recipients: a multicenter study. (2006) (38)
Glomerular Hyperfiltration and Urinary Prostaglandins in Type 1 Diabetes Mellitus (1989) (38)
Measurement of GFR with a single intravenous injection of nonradioactive iothalamate. (1992) (38)
Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trial. (2013) (38)
Polymorphisms of EDNRB, ATG, and ACE genes in salt-sensitive hypertension. (2008) (38)
COVID-19 and lombardy: TESTing the impact of the first wave of the pandemic (2020) (38)
Dissociation between antiproteinuric and antihypertensive effect of angiotensin converting enzyme inhibitors in rats. (1994) (38)
Adeno-associated virus-mediated CTLA4Ig gene transfer protects MHC-mismatched renal allografts from chronic rejection. (2006) (38)
ACE inhibition limits chronic injury of kidney transplant even with treatment started when lesions are established. (2003) (38)
The Selective Vitamin D Receptor Activator for Albuminuria Lowering (VITAL) Study: Study Design and Baseline Characteristics (2009) (38)
Preventing Left Ventricular Hypertrophy by ACE Inhibition in Hypertensive Patients With Type 2 Diabetes (2008) (38)
Regression of Renal Disease by Angiotensin II Antagonism Is Caused by Regeneration of Kidney Vasculature. (2016) (37)
Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial (2017) (37)
Nitric oxide/endothelin balance after nephron reduction. (1998) (37)
Toward novel antirejection strategies: in vivo immunosuppressive properties of CTLA4Ig. (1995) (37)
Endothelin: a mediator of renal disease progression. (1997) (37)
A simple, home-therapy algorithm to prevent hospitalisation for COVID-19 patients: A retrospective observational matched-cohort study (2021) (37)
Pathogenesis and treatment of thrombotic microangiopathy. (1997) (36)
Ways to Boost Kidney Transplant Viability: A Real Need for the Best Use of Older Donors (2006) (36)
Treatment with pegylated interferon and ribavirin for hepatitis C virus-associated severe cryoglobulinemia in a liver/kidney transplant recipient. (2007) (36)
Thromboxane receptor blockade attenuates chronic cyclosporine nephrotoxicity and improves survival in rats with renal isograft. (1992) (36)
Combined treatment with mycophenolate mofetil and an angiotensin II receptor antagonist fully protects from chronic rejection in a rat model of renal allograft. (2001) (36)
Erythropoietin, but not the correction of anemia alone, protects from chronic kidney allograft injury. (2012) (36)
Association of functional gene variants in the regulatory regions of COX‐2 gene (PTGS2) with nonmelanoma skin cancer after organ transplantation (2007) (36)
Therapy with a Selective Cannabinoid Receptor Type 2 Agonist Limits Albuminuria and Renal Injury in Mice with Type 2 Diabetic Nephropathy (2015) (36)
Pretransplant Donor Peripheral Blood Mononuclear Cells Infusion Induces Transplantation Tolerance by Generating Regulatory T Cells (2005) (36)
Progression, Remission and Regression of Chronic Renal Diseases (2016) (36)
Manipulating Sirtuin 3 pathway ameliorates renal damage in experimental diabetes (2020) (36)
Ticlopidine prevents renal disease progression in rats with reduced renal mass. (1990) (36)
B7-1 Is Not Induced in Podocytes of Human and Experimental Diabetic Nephropathy. (2016) (36)
Protein load impairs factor H binding promoting complement-dependent dysfunction of proximal tubular cells. (2009) (36)
Interleukin-1 beta and tumor necrosis factor-alpha induce gene expression and production of leukocyte chemotactic factors, colony-stimulating factors, and interleukin-6 in human mesangial cells. (1991) (35)
The thymic way to transplantation tolerance. (1995) (35)
L-arginine, the precursor of nitric oxide, abolishes the effect of estrogens on bleeding time in experimental uremia. (1991) (35)
Prostacyclin in thrombotic microangiopathy. (1987) (35)
Effect of platelet-activating factor and its specific receptor antagonist on glomerular permeability to proteins in isolated perfused rat kidney. (1988) (35)
Genetics and genetic testing in hemolytic uremic syndrome/thrombotic thrombocytopenic purpura. (2010) (35)
Role of endothelin in glomerular injury. (1993) (35)
Case Report: Developing Regulatory-compliant Electronic Case Report Forms for Clinical Trials: Experience with The Demand Trial (2009) (34)
Blood pressure, proteinuria, and phosphate as risk factors for progressive kidney disease: a hypothesis. (2013) (34)
CD133+ renal stem cells always co-express CD24 in adult human kidney tissue. (2014) (34)
Maternal and environmental risk factors for neonatal AKI and its long-term consequences (2018) (34)
Coagulation defects in uremia. (1988) (34)
Effect of Sirolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4. (2016) (34)
Superimposed nephritis: a separate entity among glomerular diseases? (1986) (34)
Lack of the Lectin-like Domain of Thrombomodulin Worsens Shiga Toxin-Associated Hemolytic Uremic Syndrome in Mice (2012) (34)
Rationale, Design, and Baseline Characteristics of ARTS-DN: A Randomized Study to Assess the Safety and Efficacy of Finerenone in Patients with Type 2 Diabetes Mellitus and a Clinical Diagnosis of Diabetic Nephropathy (2015) (34)
The metabolism of arachidonic acid by platelets in nephrotic syndrome. (1984) (34)
Thrombospondin induces glomerular mesangial cell adhesion and migration. (1992) (33)
Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia. (1996) (33)
Endothelin and eicosanoid synthesis in cultured mesangial cells. (1990) (33)
Low Levels of the Anticoagulant Activity of Protein C in Patients with Chronic Renal Insufficiency: an Inhibitor of Protein C Is Present in Uremic Plasma (1991) (33)
Engineering the vasculature of decellularized rat kidney scaffolds using human induced pluripotent stem cell-derived endothelial cells (2019) (33)
Immunophenotypic analysis of cellular infiltrate of renal allograft biopsies in patients with acute rejection after induction with alemtuzumab (Campath-1H). (2006) (33)
High-performance liquid chromatography with ultraviolet detection for therapeutic drug monitoring of everolimus. (2005) (33)
Pathophysiology of disease progression in proteinuric nephropathies. (2005) (33)
Renal transplantation: single or dual for donors aging > or =60 years? (2000) (33)
Bleeding in renal failure: a possible role of vascular prostacyclin (PGI2). (1979) (33)
Sympathetic overactivity in hypertensive patients with chronic renal disease. (1999) (33)
Preventing end-stage renal disease: the potential impact of screening and intervention in developing countries. (2003) (33)
Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers (2016) (33)
Stimulation of prostacyclin synthesis in vascular cells by mononuclear cell products. (1984) (32)
A German outbreak of haemolytic uraemic syndrome (2011) (32)
Enhanced glomerular thromboxane A2 mediates some pathophysiologic effect of platelet-activating factor in rabbit nephrotoxic nephritis: evidence from biochemical measurements and inhibitor trials. (1989) (32)
Hemostasis, prostaglandins, and renal disease (1980) (32)
Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial. (2022) (32)
Intensified inhibition of renin-angiotensin system: A way to improve renal protection? (2007) (32)
Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic Nephropathy. (2015) (32)
Thromboxane synthesis inhibition increases renal prostacyclin and prevents renal disease progression in rats with remnant kidney. (1990) (32)
Following an initial decline, glomerular filtration rate stabilizes in heart transplant patients on chronic cyclosporine. (1994) (32)
Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial (2019) (32)
ACE inhibition prevents renal failure and death in uninephrectomized MWF/Ztm rats. (1995) (31)
Both Darbepoetin Alfa and Carbamylated Erythropoietin Prevent Kidney Graft Dysfunction Due to Ischemia/Reperfusion in Rats (2011) (31)
Xenotransplantation: problems and prospects. (1997) (31)
Novel Biomarkers for Renal Diseases? None for the Moment (but One) (2016) (31)
C3a receptor blockade protects podocytes from injury in diabetic nephropathy. (2020) (31)
Automatic generation of glomerular capillary topological organization. (2001) (31)
Impact of the PPAR-γ2 Pro12Ala Polymorphism and ACE Inhibitor Therapy on New-Onset Microalbuminuria in Type 2 Diabetes: Evidence From BENEDICT (2009) (31)
Direct Reprogramming of Human Bone Marrow Stromal Cells into Functional Renal Cells Using Cell-free Extracts (2015) (30)
In renal transplantation blood cyclosporine levels soon after surgery act as a major determinant of rejection: insights from the MY.S.S. trial. (2004) (30)
Endothelial cells express the interleukin-1 receptor type I (1991) (30)
Thromboxane receptor blockade attenuates the toxic effect of cyclosporine in experimental renal transplantation. (1990) (30)
Kidney volume measurement methods for clinical studies on autosomal dominant polycystic kidney disease (2017) (30)
Mapping disparities in education across low- and middle-income countries (2019) (30)
Neurological symptoms and coma associated with doxorubicin administration during chronic cyclosporin therapy (1992) (30)
Role of enhanced glomerular synthesis of thromboxane A2 in progressive kidney disease. (1990) (30)
ADAMTS13 Predicts Renal and Cardiovascular Events in Type 2 Diabetic Patients and Response to Therapy (2013) (30)
Effect of high dose ramipril with or without indomethacin on glomerular selectivity. (2002) (30)
Prevention programs for chronic kidney disease in low-income countries (2016) (30)
Inherited thrombotic thrombocytopenic purpura (2009) (30)
SARS-CoV-2 Spike Protein 1 Activates Microvascular Endothelial Cells and Complement System Leading to Platelet Aggregation (2022) (29)
Immunomodulatory effects of mesenchymal stromal cells in solid organ transplantation (2010) (29)
Early and late scanning electron microscopy findings in diabetic kidney disease (2018) (29)
Clinical update: immunosuppression minimisation (2007) (29)
Cyclosporine Prolongs Delayed Graft Function in Kidney Transplantation: Are Rabbit Anti-Human Thymocyte Globulins the Answer? (2005) (29)
Therapeutic potential of stromal cells of non-renal or renal origin in experimental chronic kidney disease (2018) (29)
Endothelin antagonists and renal protection. (2000) (29)
DnIKK2-Transfected Dendritic Cells Induce a Novel Population of Inducible Nitric Oxide Synthase–Expressing CD4+CD25− Cells with Tolerogenic Properties (2007) (29)
Risk factors for progression of chronic kidney disease in the EPPIC trials and the effect of AST-120 (2017) (29)
Abbreviated kinetic profiles in area-under-the-curve monitoring of cyclosporine therapy. Technical note. (1998) (29)
Nitric Oxide/L-Arginine in Uremia (1999) (29)
Outcomes of patients with atypical haemolytic uraemic syndrome with native and transplanted kidneys treated with eculizumab: a pooled post hoc analysis (2017) (29)
Hyperuricemia in kidney transplantation. (2005) (29)
Mesenchymal stromal cells to promote kidney transplantation tolerance (2014) (29)
C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial. (2019) (29)
Rare Functional Variants in Complement Genes and Anti-FH Autoantibodies-Associated aHUS (2019) (29)
Acceleration of recovery in acute renal failure: from cellular mechanisms of tubular repair to innovative targeted therapies. (1996) (29)
Dual blockade of the renin-angiotensin system: the ultimate treatment for renal protection? (2005) (29)
Angiotensin-converting enzyme inhibition and calcium channel blockade both normalize early hyperfiltration in experimental diabetes, but only the former prevents late renal structural damage. (1994) (29)
Catecholamine receptor binding in rat kidney: effect of aging. (1988) (28)
Primer: strategies for identifying genes involved in renal disease (2008) (28)
Genetic abnormalities of complement regulators in hemolytic uremic syndrome: how do they affect patient management? (2005) (28)
Independent clinical research in Europe (2004) (28)
Generic cyclosporine formulations: more open questions than answers (2005) (28)
C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). (2016) (28)
Monitoring Initial Response to Angiotensin-Converting Enzyme Inhibitor–Based Regimens: An Individual Patient Data Meta-Analysis From Randomized, Placebo-Controlled Trials (2010) (28)
Factor H Competitor Generated by Gene Conversion Events Associates with Atypical Hemolytic Uremic Syndrome. (2017) (28)
Erythropoietin enhances immunostimulatory properties of immature dendritic cells (2011) (28)
Beneficial effects of calcium channel blockade on acute glomerular hemodynamic changes induced by cyclosporine. (1999) (28)
Cost-effectiveness of ACE inhibitor therapy to prevent dialysis in nondiabetic nephropathy: influence of the ACE insertion/deletion polymorphism (2009) (28)
Unrecognized pattern of von Willebrand factor abnormalities in hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. (1999) (28)
Research on renal endothelin in proteinuric nephropathies dictates novel strategies to prevent progression (2001) (28)
Aging and the kidney (2011) (28)
Methylprednisolone normalizes superoxide anion production by polymorphs from patients with ANCA-positive vasculitides. (1993) (27)
CO‐PARTICIPATION OF THROMBOXANE A2 AND LEUKOTRIENE C4 AND D4 IN MEDIATING CYCLOSPORINE‐INDUCED ACUTE RENAL FAILURE (1991) (27)
Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN (2018) (27)
Effect of dietary proteins and lipids in patients with membranous nephropathy and nephrotic syndrome. (1991) (27)
Prolonged bleeding time and increased vascular prostacyclin in rats with chronic renal failure: effects of conjugated estrogens. (1988) (27)
Genetic testing in the diagnosis of chronic kidney disease: recommendations for clinical practice (2021) (27)
Supranormal von Willebrand factor multimers in scleroderma. (1989) (27)
Erratum: Global, regional, and national levels of maternal mortality, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 (The Lancet (2016) 388(10053) (1775–1812)(S0140673616314702)(10.1016/S0140-6736(16)31470-2)) (2017) (27)
Renal Medicine 3 Kidney regeneration (2010) (27)
Doppler Ultrasonography in Posttransplant Renal Artery Stenosis: A Reliable Tool for Assessing Effectiveness of Revascularization? Transplantation 2003; 76:147. (2003) (27)
Translational Mini‐Review Series on Complement Factor H: Therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis (2007) (27)
Addition of cyclic angiotensin-(1-7) to angiotensin-converting enzyme inhibitor therapy has a positive add-on effect in experimental diabetic nephropathy. (2019) (27)
Renoprotective effects of renin-angiotensin-system inhibitors (2006) (27)
Tissue plasminogen activator therapy of rabbit nephrotoxic nephritis. (1990) (27)
Renal biopsy in patients with acute renal failure and prolonged bleeding time: a preliminary report. (1985) (27)
At the peak of Covid-19 age and disease severity but not comorbidities are predictors of mortality. Covid-19 burden in Bergamo, Italy. (2020) (27)
Subcutaneous xenotransplantation of bovine pancreatic islets. (2005) (27)
Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial. (2018) (27)
Renal transplantation: can we reduce calcineurin inhibitor/stop steroids? Evidence based on protocol biopsy findings. (2003) (26)
Treatment of Congenital Thrombotic Thrombocytopenic Purpura With Eculizumab. (2015) (26)
Effects of angiotensin-converting enzyme inhibition on glomerular capillary wall ultrastructure in MWF/Ztm rats. (1994) (26)
BRAF Signaling Pathway Inhibition, Podocyte Injury, and Nephrotic Syndrome. (2017) (26)
Severe early acute humoral rejection resulting in allograft loss in a renal transplant recipient with Campath-1H induction therapy. (2005) (26)
Recovery of blood mononuclear cell calcineurin activity segregates two populations of renal transplant patients with different sensitivities to cyclosporine inhibition. (1996) (26)
Complement Alternative Pathway Deficiency in Recipients Protects Kidney Allograft From Ischemia/Reperfusion Injury and Alloreactive T Cell Response (2017) (26)
Proteinuria in diabetic nephropathy: Treatment and evolution (2003) (26)
Outcome of renal transplantation from very old donors. (2009) (26)
Proteinuria and its consequences in renal disease (2003) (26)
Role of platelets in progressive glomerular diseases (1995) (26)
Circulating anti-PLA2R autoantibodies to monitor immunological activity in membranous nephropathy. (2011) (26)
Thymic microchimerism correlates with the outcome of tolerance-inducing protocols for solid organ transplantation. (2001) (26)
Cyclooxygenase products and atrial natriuretic peptide modulate renal response to endothelin. (1990) (25)
New insights into circulating cell-endothelium interactions and their significance for glomerular pathophysiology. (1995) (25)
Platelet-activating factor receptor blocking reduces proteinuria and improves survival in lupus autoimmune mice. (1991) (25)
Enzyme replacement therapy and Fabry nephropathy. (2010) (25)
Diabetes mellitus and chronic kidney disease in the Eastern Mediterranean Region: findings from the Global Burden of Disease 2015 study (2017) (25)
PPARγ2 P12A polymorphism and albuminuria in patients with type 2 diabetes: a meta-analysis of case-control studies. (2011) (25)
The diagnosis of renal involvement in non‐insulin-dependent diabetes mellitus (1997) (25)
Transforming Growth Factor-β1 Is Up-Regulated by Podocytes in Response to Excess Intraglomerular Passage of Proteins (2002) (25)
Engineered Kidney Tubules for Modeling Patient-Specific Diseases and Drug Discovery (2018) (24)
Glomerular filtration rate gfr extracellular fluid volume ecv and atrial natriuretic factor anf in insulin dependent diabetics (1988) (24)
Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies (2007) (24)
Cyclosporine enhances leukocyte adhesion to vascular endothelium under physiologic flow conditions. (1996) (24)
Ofatumumab for multirelapsing membranous nephropathy complicated by rituximab-induced serum-sickness (2020) (24)
Inhibition of human platelet aggregation by parathyroid hormone. Is cyclic AMP implicated? (1985) (24)
Sequence of glomerular changes in experimental endotoxemia: a possible model of hemolytic uremic syndrome. (1989) (24)
A logistic-regression model provides novel guidelines to maximize the anti-acute rejection properties of cyclosporine with a minimum of toxicity. (1996) (24)
Role of renal prostaglandins in normal and nephrotic rats with diet-induced hyperfiltration. (1986) (24)
Effects of Combined Ezetimibe and Simvastatin Therapy as Compared With Simvastatin Alone in Patients With Type 2 Diabetes (2010) (24)
17β-Estradiol corrects hemostasis in uremic rats by limiting vascular expression of nitric oxide synthases (2000) (24)
Albumin concentration in the Bowman's capsule: multiphoton microscopy vs micropuncture technique. (2007) (24)
Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy (2018) (23)
Rationale and population-based prospective cohort protocol for the disadvantaged populations at risk of decline in eGFR (CO-DEGREE) (2019) (23)
Defective platelet aggregation in response to platelet-activating factor in uremia associated with low platelet thromboxane A2 generation. (1992) (23)
Systems biology to battle vascular disease. (2010) (23)
The future of renoprotection. (2005) (23)
Measuring the availability of human resources for health and its relationship to universal health coverage for 204 countries and territories from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019 (2022) (23)
[Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy]. (2001) (23)
Routine renin-angiotensin system blockade in renal transplantation? (2002) (23)
Renal and metabolic effects of insulin lispro in type 2 diabetic subjects with overt nephropathy. (2003) (23)
Slowing the progression of diabetic nephropathy. (1993) (23)
ACE and SGLT2 inhibitors: the future for non‐diabetic and diabetic proteinuric renal disease (2017) (23)
Effect of Low-Dose Aspirin on Fetal and Maternal Generation of Thromboxane by Platelets in Women at Risk for Pregnancy-Induced Hypertension (1990) (23)
Failure to predict cyclosporine area under the curve using a limited sampling strategy. (1993) (23)
Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial. (2013) (23)
Kidney injury molecule 1: in search of biomarkers of chronic tubulointerstitial damage and disease progression. (2009) (23)
Glomerular hyperfiltration (2022) (23)
Rabbit anti‐rat thymocyte immunoglobulin preserves renal function during ischemia/reperfusion injury in rat kidney transplantation (2011) (23)
Effect of aspirin and sulindac in rabbit nephrotoxic nephritis. (1986) (23)
A long term, randomized clinical trial to evaluate the effects of ramipril on the evolution of renal function in chronic nephropathies (1991) (23)
Angiotensin-converting enzyme inhibition prevents loss of glomerular hydraulic permeability in passive heymann nephritis. (1999) (22)
Urinary excretion of platelet-activating factor in haemolytic uraemic syndrome (1992) (22)
Blood Pressure and Metabolic Effects of Acetyl-l-Carnitine in Type 2 Diabetes: DIABASI Randomized Controlled Trial (2018) (22)
The renoprotective action of angiotensin-converting enzyme inhibitors in diabetes. (1996) (22)
Prevention of progression and remission/regression strategies for chronic renal diseases: can we do better now than five years ago? (2005) (22)
Platelet-activating factor alters glomerular barrier size selectivity for macromolecules in rats. (1991) (22)
Renal prostacyclin biosynthesis is reduced in children with hemolytic-uremic syndrome in the context of systemic platelet activation. (1992) (22)
Renal response to atrial peptides is reduced in experimental nephrosis. (1987) (22)
Decision time for pancreatic islet-cell transplantation (2008) (22)
Differential inhibition by aspirin of platelet thromboxane and renal prostaglandins in the rat. (1989) (22)
Selective inhibition of platelet thromboxane generation with low-dose aspirin does not protect rats with reduced renal mass from the development of progressive disease. (1989) (22)
Sirtuin3 Dysfunction Is the Key Determinant of Skeletal Muscle Insulin Resistance by Angiotensin II (2015) (22)
Xenogeneic serum promotes leukocyte-endothelium interaction under flow through two temporally distinct pathways: role of complement and nuclear factor-kappaB. (1999) (22)
Acetyl glycerylphosphorylcholine aggregates human platelets through two distinct pathways, both dependent on arachidonic acid metabolism. (1985) (22)
Genetics of Immune-Mediated Glomerular Diseases: Focus on Complement. (2017) (22)
Acute kidney injury: more awareness needed, globally (2015) (22)
The role of B7-1 in proteinuria of glomerular origin (2018) (22)
Continuum of renoprotection with Losartan at all stages of type 2 diabetic nephropathy: A post hoc analysis of the RENAAL trial results: A post hoc analysis of the RENAAL trial results (2004) (22)
Complement factor H and hemolytic uremic syndrome. (2001) (21)
The Role of Angiotensin II in Parietal Epithelial Cell Proliferation and Crescent Formation in Glomerular Diseases. (2017) (21)
Thymus-mediated immune tolerance to renal allograft is donor but not tissue specific. (1991) (21)
Eliminating Treatable Deaths Due to Acute Kidney Injury in Resource‐Poor Settings (2015) (21)
Skin fibroblasts from a patient with Glanzmann's thrombasthenia do not induce fibrin clot retraction. (1977) (21)
Urinary excretion of platelet activating factor in patients with immune-mediated glomerulonephritis. (1993) (21)
Accelerating the Depletion of Circulating Anti-Phospholipase A2 Receptor Antibodies in Patients with Severe Membranous Nephropathy: Preliminary Findings with Double Filtration Plasmapheresis and Ofatumumab (2019) (21)
RENAL BIOPSY IN PATIENTS WITH ACUTE RENAL FAILURE AND PROLONGED BLEEDING TIME (1984) (21)
Aldosterone and progression of kidney disease (2009) (21)
Relationships among natriuresis, atrial natriuretic peptide and insulin in insulin-dependent diabetes. (1992) (21)
Liver transplantation for aHUS: still needed in the eculizumab era? (2016) (21)
Data Sharing Under the General Data Protection Regulation (2021) (21)
Burden of non-communicable diseases among adolescents aged 10–24 years in the EU, 1990–2019: a systematic analysis of the Global Burden of Diseases Study 2019 (2022) (21)
Glutathione S‐transferase and CYP1A1 gene polymorphisms and non‐melanoma skin cancer risk in Italian transplanted patients (2006) (21)
West Meets East (2015) (21)
Old Donors for Kidney Transplantation: How Old? (2010) (21)
Kidney failure stabilizes after a two-decade increase: impact on global (renal and cardiovascular) health. (2006) (21)
Platelet-activating factor mediates angiotensin II-induced proteinuria in isolated perfused rat kidney. (1997) (21)
Non-immune interventions to protect kidney allografts in the long term. (2010) (20)
Inhibitors to Prevent End-Stage Renal Disease : When to Start and Why Possibly Never to Stop : A Post Hoc Analysis of the REIN Trial Results (2001) (20)
Assessing Renal Function by GFR Prediction Equations in Kidney Transplantation (2005) (20)
A previously unrecognized role of C3a in proteinuric progressive nephropathy (2016) (20)
Combined neprilysin and RAS inhibition for the failing heart: straining the kidney to help the heart? (2015) (20)
Nephrology research—the past, present and future (2015) (20)
Glutathione S-transferase and CYP1A1 gene polymorphisms and non-melanoma skin cancer risk in Italian transplanted patients. (2011) (20)
Endothelin receptor antagonists: which are the therapeutic perspectives in renal diseases? (1998) (20)
Nitric Oxide Synthetic Capacity in Relation to Dialysate Temperature (2004) (20)
Global, regional, and national sex differences in the global burden of tuberculosis by HIV status, 1990–2019: results from the Global Burden of Disease Study 2019 (2021) (20)
Prostacyclin (PGI2) and bleeding time in uremic patients. (1977) (20)
Mesenchymal stromal cells to control donor-specific memory T cells in solid organ transplantation (2015) (20)
Sirolimus to replace calcineurin inhibitors? Too early yet (2009) (20)
Primary prevention of renal failure in diabetic patients: the Bergamo Nephrologic Diabetes Complication Trial. (1998) (20)
Mortality landscape in the global burden of diseases, injuries and risk factors study. (2014) (20)
Antihypertensive effects of double the maximum dose of valsartan in African–American patients with type 2 diabetes mellitus and albuminuria (2010) (20)
Safety of Iohexol Administration to Measure Glomerular Filtration Rate in Different Patient Populations: A 25-Year Experience (2018) (20)
Dual Renin-Angiotensin System Blockade for Nephroprotection: Still under Scrutiny (2014) (20)
Rituximab for membranous nephropathy and immune disease: less might be enough (2009) (20)
Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). (2019) (20)
Angiotensin-converting enzyme inhibition ameliorates the defect in glomerular size selectivity in hyponatremic hypertensive syndrome. (1989) (20)
C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19 (2021) (20)
Increased fragmentation of von Willebrand factor, due to abnormal cleavage of the subunit, parallels disease activity in recurrent hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and discloses predisposition in families. The Italian Registry of Familial and Recurrent HUS/TTP. (1999) (19)
Methylprednisolone dosage effects on peripheral lymphocyte subpopulations and eicosanoid synthesis. (1992) (19)
Angiotensin II receptor antagonists and treatment of hypertension and renal disease (1998) (19)
Combining lisinopril and l-arginine slows disease progression and reduces endothelin-1 in passive Heymann nephritis. (2003) (19)
Which antihypertensive drugs are the most nephroprotective and why? (2010) (19)
Renal Bioengineering with Scaffolds Generated from Rat and Pig Kidneys (2014) (19)
Losartan in diabetic nephropathy (2004) (19)
Haemolytic uraemic syndrome: therapeutic effect of plasma infusion (1983) (19)
A Home-Treatment Algorithm Based on Anti-inflammatory Drugs to Prevent Hospitalization of Patients With Early COVID-19: A Matched-Cohort Study (COVER 2) (2021) (19)
Recurrent abortion with lupus anticoagulant, and pre‐eclampsia: a common final pathway for two different diseases? Case report (1986) (19)
17 beta-estradiol is the most active component of the conjugated estrogen mixture active on uremic bleeding by a receptor mechanism. (1990) (19)
Managing hypertension in diabetic patients – focus on trandolapril/verapamil combination (2007) (19)
Successes and disappointments with clinical islet transplantation. (2010) (19)
Discordant phenotype in monozygotic twins with renal coloboma syndrome and a PAX2 mutation (2012) (19)
Lessons from the Di Bella affair (1999) (19)
Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm. (2013) (19)
Thrombotic thrombocytopenic purpura--a deficiency of plasma factors regulating platelet-vessel-wall interaction? (1978) (18)
Epidemiology of the hemolytic uremic syndrome. (1991) (18)
Non-muscle myosins and the podocyte (2012) (18)
Thrice-Weekly In-Center Nocturnal Hemodialysis: An Effective Strategy to Optimize Chronic Dialysis Therapy (2009) (18)
Endothelial cells express the interleukin-1 receptor type I. (1991) (18)
Targeting the Renin Angiotensin System in Dialysis Patients (2011) (18)
Non-Shiga toxin-associated hemolytic uremic syndrome (2006) (18)
Modulating the profit motive to meet needs of the less-developed world (2001) (18)
Oxford textbook of clinical nephrology (2015) (18)
Meeting report on the Bellagio Conference 'prevention of vascular diseases in the emerging world: An approach to global health equity'. (2006) (18)
Preventing end-stage renal disease: the potential impact of screening and intervention in developing countries. (2003) (18)
Long Covid: where we stand and challenges ahead (2022) (18)
Role of platelet-activating factor in renal immune injury and proteinuria. (1990) (18)
Functional implications of decreased renal cortical atrial natriuretic peptide binding in experimental diabetes. (1990) (18)
Latest treatment strategies for membranous nephropathy (2007) (18)
Mitochondrial-dependent Autoimmunity in Membranous Nephropathy of IgG4-related Disease (2015) (17)
Activation of porcine endothelium in response to xenogeneic serum causes thrombosis independently of platelet activation (2005) (17)
Renal handling of sodium in the nephrotic syndrome. (1993) (17)
TRANSPLANTS (1968) (17)
Effect of Trandolapril on Regression of Retinopathy in Hypertensive Patients with Type 2 Diabetes: A Prespecified Analysis of the Benedict Trial (2010) (17)
Acute kidney injury in low-income and middle-income countries: no longer a death sentence. (2016) (17)
Mechanism of progression of renal disease: growth factors and related mechanisms. (1998) (17)
Mycophenolate Mofetil Versus Azathioprine in Organ Transplantation (2009) (17)
Thrombotic microangiopathy: What not to learn from a meta-analysis (2009) (17)
Complement Activation Contributes to the Pathophysiology of Shiga Toxin-Associated Hemolytic Uremic Syndrome (2019) (17)
Nonimmunosuppressive therapy of membranous nephropathy. (2003) (17)
α1-antitrypsin therapy in a case of thrombotic thrombocytopenic purpura (1995) (17)
Comparison of different cyclosporine immunoassays to monitor C0 and C2 blood levels from kidney transplant recipients: not simply overestimation. (2005) (17)
Intermediate volume on computed tomography imaging defines a fibrotic compartment that predicts glomerular filtration rate decline in autosomal dominant polycystic kidney disease patients. (2011) (17)
Increased urinary excretion of platelet activating factor in mice with lupus nephritis. (1991) (17)
Renal Primordia Activate Kidney Regenerative Events in a Rat Model of Progressive Renal Disease (2015) (17)
Immunosuppressive therapy abrogates unresponsiveness to renal allograft induced by thymic recognition of donor antigens. (1995) (17)
Thrombotic microangiopathies: from animal models to human disease and cure. (2011) (17)
In vivo platelet activation with in vitro hyperaggregability to arachidonic acid in renal allograft recipients. (1983) (16)
The pivotal role of the endothelial cell in the pathogenesis of hus (1992) (16)
Home as the new frontier for the treatment of COVID-19: the case for anti-inflammatory agents (2022) (16)
Fighting renal diseases in poor countries: building a global fund with the help of the pharmaceutical industry. (2004) (16)
Erratum: Proximal tubular cells promote fibrogenesis by TGF-β1-mediated induction of peritubular myofibroblasts (Kidney International (2002) 6 (2066-2077)) (2002) (16)
Blocking cell microtubule assembly inhibits the alloimmune response in vitro and prolongs renal allograft survival by inhibition of Th1 and sparing of Th2 cell function in vivo. (1995) (16)
Evidence against a pathogenetic role for endothelin in preeclampsia (1993) (16)
Management of chronic kidney disease and its risk factors in eastern Nepal. (2014) (16)
Pretreatment blood pressure reliably predicts progression of chronic nephropathies. GISEN Group. (2000) (16)
Trends in cardiovascular diseases burden and vascular risk factors in Italy: The Global Burden of Disease study 1990-2017. (2020) (16)
Pharmacological and clinical profile of valsartan. (1998) (16)
PROSTACYCLIN DEFICIENCY IN THROMBOTIC MICROANGIOPATHY (1981) (15)
The potential of endothelin antagonism as a therapeutic approach (2004) (15)
Nonviral and Viral Gene Transfer to the Kidney in the Context of Transplantation (2000) (15)
Evidence of the central role of the thymus in the induction of donor-specific unresponsiveness to a renal allograft. (1992) (15)
Preliminary results of intrathymic injection of donor cells to prevent acute rejection in human heart transplantation. (1995) (15)
Acquired transplant tolerance (1997) (15)
The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy (2017) (15)
Optimization of cyclosporine therapy in the Neoral era: abbreviated AUC, single blood sampling? (2001) (15)
Role of endothelin in the development of glomerulosclerosis. (1996) (15)
Colchicine allows prolonged survival of highly reactive renal allograft in the rat. (1993) (15)
Heparin-induced thrombocytopenia--background and implications for haemodialysis. (1996) (15)
The European Rare Kidney Disease Registry (ERKReg): objectives, design and initial results (2021) (15)
Clinical use of computational modeling for surgical planning of arteriovenous fistula for hemodialysis (2017) (15)
Prevalence of Hypertension and Diabetes and Coexistence of Chronic Kidney Disease and Cardiovascular Risk in the Population of the Republic of Moldova (2012) (15)
Proteinuria: Increased angiotensin-receptor blocking is not the first option (2009) (15)
The role of the endothelium in hemolytic uremic syndrome. (2001) (15)
Alteration of thyroid hormone signaling triggers the diabetes-induced pathological growth, remodeling, and dedifferentiation of podocytes. (2019) (15)
Inhibitors of the renin-angiotensin system reduce the rate of GFR decline and end-stage renal disease in patients with severe renal insufficiency. (2002) (15)
Recognition and management of community-acquired acute kidney injury in low-resource settings in the ISN 0by25 trial: A multi-country feasibility study (2021) (14)
Kidney transplant tolerance associated with remote autologous mesenchymal stromal cell administration (2019) (14)
Low-protein diet and glomerular size-selective function in membranous glomerulopathy. (1991) (14)
Endothelin in the progressive renal disease of glomerulopathies. (1995) (14)
Microvascular and Macrovascular Diseases of the Kidney (2011) (14)
Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial (2017) (14)
Novel effective drugs for diabetic kidney disease? or not? (2014) (14)
Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial. (2019) (14)
Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study (2021) (14)
Overview of randomised trials of ACE inhibitors (2006) (14)
Advances in the pathology of glomerular diseases. (2013) (14)
Xenogeneic human serum promotes leukocyte adhesion to porcine endothelium under flow conditions, possibly through the activation of the transcription factor NF‐κB (1998) (14)
Cadaver kidney allocation in the north Italy transplant program on the eve of the new millennium. (1998) (14)
Prevention and Transplantation in Chronic Kidney Disease: What Is Achievable in Emerging Countries? (2010) (14)
Building a network of ADPKD reference centres across Europe: the EuroCYST initiative. (2014) (14)
Cyclosporine Formulation and Kaposi’s Sarcoma after Renal Transplantation (2005) (14)
Perioperative Minimal Induction Therapy: A Further Step toward More Effective Immunosuppression in Transplantation (2012) (13)
Third‐party bone marrow–derived mesenchymal stromal cell infusion before liver transplantation: A randomized controlled trial (2020) (13)
Effect of ACE inhibition on glomerular permselectivity and tubular albumin concentration in the renal ablation model. (2011) (13)
Erratum: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease (Annals of Internal Medicine (2001) 135 (73-87)) (2002) (13)
Human renal cortex generates prostacyclin-like activity. (1978) (13)
Favorable Effect of Cotransfection with TGF-β and CTLA4Ig of the Donor Kidney on Allograft Survival (2004) (13)
COVID-19 pandemic and total mortality in the first six months of 2020 in Italy (2020) (13)
Transplant tolerance: progress and challenges. (2010) (13)
Calcitonin gene-related peptide reduces renal vascular resistance and modulates ET-1-induced vasoconstriction. (1994) (13)
Why rare diseases? (2011) (13)
A unifying hypothesis for renal scarring linking protein trafficking to the different mediators of injury. (2000) (13)
Renal metabolism and urinary excretion of platelet-activating factor in the rat. (1990) (13)
CTLA4Ig alone or in combination with low-dose cyclosporine fails to reverse acute rejection of renal allograft in the rat. (1996) (13)
A Multidrug, Antiproteinuric Approach to Alport Syndrome: A Ten-Year Cohort Study (2015) (13)
Novel therapies of lupus nephritis (2008) (13)
Predicting end-stage renal disease: Bayesian perspective of information transfer in the clinical decision-making process at the individual level. (2003) (13)
Effects of Combined Ezetimibe and Simvastatin Therapy as Compared With Simvastatin Alone in Patients With Type 2 Diabetes: A Prospective Randomized Double-Blind Clinical Trial (2010) (13)
Lipid oxidative stress and the anti-inflammatory properties of statins and ACE inhibitors. (2005) (13)
Urinary proteome signature of Renal Cysts and Diabetes syndrome in children (2019) (13)
Polycystic kidney disease: Do mTOR inhibitors still have a future in ADPKD? (2010) (13)
ACE inhibitors and AT1 receptor antagonists: is two better than one? (2002) (13)
The diabetic CKD patient--a major cardiovascular challenge. (2010) (13)
Prognosis of diabetic nephropathy: how to improve the outcome. (1998) (12)
Health services: an Italian market. (1996) (12)
Glucose-induced changes in renal haemodynamics in proteinuric Type 1 (insulin-dependent) diabetic patients: inhibition by acetylsalicilic acid infusion (1993) (12)
Nitric oxide synthesis and L-arginine in uremia. (1997) (12)
The June 2003 Barry M. Brenner Comgan lecture. The future of renoprotection: frustration and promises. (2003) (12)
Hyperhomocysteinemia and increased risk of retinopathy: a cross-sectional, case-control study in patients with type 2 diabetes. (2002) (12)
Chronic kidney disease in sub-Saharan Africa: a public health priority. (2014) (12)
Repairing renal lesions: will VEGF be the builder? (2000) (12)
Influence of antacid administrations on aspirin absorption in patients with chronic renal failure on maintenance hemodialysis. (1988) (12)
Limited Sampling Strategies for the Estimation of Sirolimus Daily Exposure in Kidney Transplant Recipients on a Calcineurin Inhibitor—Free Regimen (2009) (12)
Dealing with Renin-Angiotensin Inhibitors, Don’t Mind Serum Creatinine (2012) (12)
Novel mechanism(s) implicated in tubular albumin reabsorption and handling. (2001) (12)
Renal handling of aspirin in the rat. (1989) (12)
Nephrology in developing countries: the ISN's story (2014) (12)
Review: Potential protective effects of telmisartan on renal function deterioration (2006) (12)
Toward longitudinal studies of hemodynamically induced vessel wall remodeling (2018) (12)
Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura (2010) (12)
Renal metabolism and urinary excretion of thromboxane B2 in the rat. (1989) (12)
Left ventricular dysfunction in ADPKD and effects of octreotide-LAR: A cross-sectional and longitudinal substudy of the ALADIN trial. (2019) (12)
Heparin for Hemodialysis: Practical Guidelines for Administration and Monitoring (1984) (12)
Supernatant of endothelial cells exposed to laminar flow inhibits mesangial cell proliferation. (1993) (12)
Oral acetyl-L-carnitine therapy and insulin resistance. (2010) (12)
The KIDSTEM European Research Training Network (2007) (12)
Epidemiology of End-Stage Renal Failure: The Burden of Kidney Diseases to Global Health (2017) (12)
ADAMTS13 Secretion and Residual Activity among Patients with Congenital Thrombotic Thrombocytopenic Purpura with and without Renal Impairment. (2015) (12)
Chronic Nephropathies: Individual Risk for Progression to End-Stage Renal Failure as Predicted by an Integrated Probabilistic Model (2003) (12)
Effect of Timing and Complement Receptor Antagonism on Intragraft Recruitment and Pro-Tolerogenic Effects of Mesenchymal Stromal Cells in Murine Kidney Transplantation. (2019) (12)
Morphometrical analysis of glomerular changes induced by cyclosporine in the rat. (1991) (12)
The renoprotective potential of endothelin receptor antagonists (1997) (11)
What is the basis for the use of steroids in the treatment of idiopathic membranous nephropathy? (1987) (11)
Hyperparathyroidism does not influence the abnormal primary haemostasis in patients with chronic renal failure. (1989) (11)
Inhibiting angiotensin-converting enzyme promotes renal repair by modulating progenitor cell activation. (2016) (11)
Inhibition of TGF-beta expression: a novel role for thiazolidinediones to implement renoprotection in diabetes. (2007) (11)
Are HUS and TTP genetically determined? (1998) (11)
Prevention of Transplant Rejection (1997) (11)
CFH and CFHR Copy Number Variations in C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis (2021) (11)
Embryonic Stem Cells, Derived Either after In Vitro Fertilization or Nuclear Transfer, Prolong Survival of Semiallogeneic Heart Transplants (2011) (11)
Preliminary report: renal thromboxane A2 synthesis in children with frequent relapsing nephrotic syndrome (1990) (11)
Abatacept in B7-1-positive proteinuric kidney disease. (2014) (11)
Mesenchymal stromal cells in kidney transplantation (2019) (11)
The Nrf 2 pathway in the progression of renal disease (2014) (11)
Posttransplant immunosuppression in highly sensitized patients. (2009) (11)
Hemolytic uremic syndrome associated with verocytotoxin-producing Escherichia coli infection in acquired immunodeficiency syndrome [letter] (1990) (11)
Acute Kidney Injury in Poor Countries Should No Longer Be a Death Sentence: The ISN ‘0 by 25' Project (2015) (11)
Bergamo and Covid-19: How the Dark Can Turn to Light (2020) (11)
Pharmacokinetic/pharmacodynamic drug interaction between rosiglitazone and mycophenolate mofetil in kidney transplantation: a case report. (2008) (11)
The ERA-EDTA Working Group on inherited kidney disorders. (2012) (11)
Role of platelet-activating factor in primary hemostasis. (1988) (11)
Complement hyperactivation may cause atypical haemolytic uraemic syndrome--gain-of-function mutations in factor B. (2007) (11)
Effects of Rosuvastatin on Glomerular Capillary Size-Selectivity Function in Rats with Renal Mass Ablation (2007) (11)
The Cost of Patients with Chronic Kidney Failure Before Dialysis: Results from the IRIDE Observational Study (2017) (11)
Is regression of chronic nephropathies a therapeutic target? (2005) (11)
FK 506 does not affect the glomerular filtration rate and renal plasma flow in the rat. (1991) (11)
Factor VIII--related protein on vascular intima of patients with chronic renal failure and prolonged bleeding times. (1978) (11)
Kidney Transplantation in Patients With Atypical Hemolytic Uremic Syndrome: A Therapeutic Dilemma (or Not)? (2017) (11)
Selective dietary restriction of protein and calorie intakes prevents spontaneous proteinuria in male MWF rats. (1997) (11)
Interleukin-1 regulates cytokine gene expression in human mesangial cells through the interleukin-1 receptor type 1. (1992) (11)
Eicosanoids and platelet activating factor as possible mediators of injury in experimental nephropathies. (1989) (11)
Abnormal platelet function in haemodialysed patients: current concepts. (1979) (11)
Emerging drugs for diabetic nephropathy (2005) (11)
Current and Future Immunosuppressive Therapies Following Transplantation (2001) (10)
Pharmacokinetic study of the new cyclosporine-A formulation (Neoral) in adult allogeneic bone marrow transplant recipients. (2001) (10)
International Society of Nephrology's perspective on the emergence of chronic kidney diseases of unknown/undetermined etiology. (2014) (10)
Immunomodulation by intrathymic injection of donor leukocytes in rhesus monkeys. (2001) (10)
Spironolactone Plus Full-Dose ACE Inhibition in Patients with Idiopathic Membranous Nephropathy and Nephrotic Syndrome: Does It Really Work? (2010) (10)
Need for chronic kidney disease prevention programs in disadvantaged populations. (2015) (10)
How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients? (1998) (10)
Trends in cardiovascular diseases burden and vascular risk factors in Italy: The Global Burden of Disease study 1990-2017. (2021) (10)
CHAPTER 28 – Thrombotic Microangiopathies, Including Hemolytic Uremic Syndrome (2010) (10)
Kidney transplantation : strategies to prevent organ rejection (2004) (10)
Propionyl-L-carnitine prevents early graft dysfunction in allogeneic rat kidney transplantation. (2008) (10)
Excess total mortality during the Covid-19 pandemic in Italy: updated estimates indicate persistent excess in recent months (2022) (10)
The Lupus Anticoagulant (1984) (10)
Therapeutic Plasma Exchange in Neonates and Infants: Successful Use of a Miniaturized Machine (2017) (10)
Low‐Dose Rituximab for Posttransplant Recurrent Membranous Nephropathy (2010) (10)
How much must blood pressure be reduced in order to obtain the remission of chronic renal disease? (2000) (10)
Kidney Transplantation, Bioengineering, and Regeneration (2017) (10)
ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD. (2017) (10)
One or two marginal organs for kidney transplantation? (2002) (10)
Transplantation-Induced Ischemia-Reperfusion Injury Modulates Antigen Presentation by Donor Renal CD11c+F4/80+ Macrophages through IL-1R8 Regulation. (2020) (10)
Treating the kidney to cure the heart. (2008) (9)
An Unanticipated Role for Survivin in Organ Transplant Damage (2014) (9)
Transplant tolerance: will genes protect the graft? (1998) (9)
Achieving remission of proteinuria in childhood CKD (2017) (9)
High-performance liquid chromatographic determination of iothalamic acid in human plasma and urine. (1991) (9)
Disaster medicine and response: Optimizing life-saving potential. (2018) (9)
ABNORMAL TISSUE REPAIR IN GLANZMANN'S THROMBASTHENIA (1977) (9)
Prognosis and determinants of serum PTH changes over time in 1-5 CKD stage patients followed in tertiary care (2018) (9)
Transplantation: Time to rethink immunosuppression by mTOR inhibitors? (2009) (9)
Complement Factor H Gene Abnormalities in Haemolytic Uraemic Syndrome: From Point Mutations to Hybrid Gene (2006) (9)
Acute Kidney Injury and Hemolytic Anemia Secondary to Mycoplasma pneumoniae Infection (2017) (9)
A novel interpretation of the role of von Willebrand factor in thrombotic microangiopathies based on platelet adhesion studies at high shear rate flow. (2000) (9)
Effect of cigarette smoking on renal function and vascular endothelium. (2000) (9)
Xenotransplantation in the 21st Century (2002) (9)
Renoprotective effect of ACE inhibitors: dissecting the molecular clues and expanding the blood pressure goal. (1999) (9)
Renal protection: progression, regression, remission from nephropathy beyond blood pressure control. (2000) (9)
Novel strategies to retard renal disease progression: combining ACE inhibition with endothelin receptor blocking? (1998) (9)
Steroids and Adriamycin nephrosis. (1984) (9)
Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial (2019) (9)
Determining the Optimal Protocol for Measuring an Albuminuria Class Transition in Clinical Trials in Diabetic Kidney Disease. (2016) (9)
Adenoviral-mediated gene transfer restores plasma ADAMTS13 antigen and activity in ADAMTS13 knockout mice (2009) (9)
Hypertension after kidney transplantation: an important, but still neglected issue. (2011) (9)
Progression of proteinuric diabetic and nondiabetic renal diseases: a possible role for renal endothelin. (1997) (9)
Allograft rejection: acute and chronic studies. (2008) (9)
A RECURRENT QUESTION FROM A PRIMARY CARE PHYSICIAN: HOW SHOULD I TREAT MY COVID-19 PATIENTS AT HOME? (2020) (9)
Do attributes of persons with chronic kidney disease differ in low-income and middle-income countries compared with high-income countries? Evidence from population-based data in six countries (2017) (9)
Thrombotic microangiopathy: E. coli O104:H4 German outbreak: a missed opportunity (2012) (9)
Idiopathic membranous nephropathy: back to the future? (2013) (9)
Another Piece of the Puzzle of Podocyte B7-1 Expression: Lupus Nephritis (2016) (8)
Transplantation tolerance. A complex scenario awaiting clinical applicability. (2005) (8)
Treatment of idiopathic membranous glomerulopathy. (1994) (8)
Impediments to successful gene transfer to the kidney in the context of transplantation and how to overcome them. (2002) (8)
Intermittent heparin treatment does not induce hypercoagulability in haemodialysed patients. (1980) (8)
Empagliflozin protects glomerular endothelial cell architecture in experimental diabetes through the VEGF‐A/caveolin‐1/PV‐1 signaling pathway (2022) (8)
A First Step toward a New Approach to Treating Membranous Nephropathy. (2019) (8)
Impact of a Complement Factor H Gene Variant on Renal Dysfunction, Cardiovascular Events, and Response to ACE Inhibitor Therapy in Type 2 Diabetes (2019) (8)
Impact of the post‐COVID‐19 condition on health care after the first disease wave in Lombardy (2022) (8)
Platelet hypersensitivity in the nephrotic syndrome. (1979) (8)
The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics (2021) (8)
Does MRI trump pathology? A new era for staging and monitoring of kidney fibrosis. (2019) (8)
Identification of a novel gene--SSK1--in human endothelial cells exposed to shear stress. (1998) (8)
Misleading meta‐analysis: a need to look beyond the headlines (2007) (8)
Low‐dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy‐induced hypertension (1993) (8)
Drugs and kidney (1986) (8)
Metabolism of arachidonic acid in isolated glomeruli from pig kidney. (1988) (8)
Oral zeranol shortens the prolonged bleeding time of uremic rats. (1990) (8)
Pathophysiology of Chronic Kidney Disease (2009) (8)
Reply to the Comment by Dr. Cure on “Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade” (2020) (8)
The role of vasoactive molecules of endothelial origin in the pathophysiology of normal pregnancy and pregnancy-induced hypertension. (1996) (8)
Renoprotection: clues from knockout models of rare diseases. (2003) (8)
More about Factor H Autoantibodies in Membranous Nephropathy. (2019) (8)
Improving diagnosis for rare diseases: the experience of the Italian undiagnosed Rare diseases network (2020) (7)
Interleukin-6 stimulates gene expression of extracellular matrix components in bovine mesangial cells in culture (1993) (7)
Renin-angiotensin system, proteinuria, and tubulointerstitial damage. (2001) (7)
Turnour necrosis factor stimulates endothelin-1 gene expression in cultured bovine endothelial cells (1992) (7)
Investigational drugs for diabetic nephropathy. (2008) (7)
Rare Kidney Diseases (2001) (7)
The effects of nonsteroidal anti-inflammatory drugs on glomerular filtration of proteins and their therapeutic utility. (1995) (7)
Proinflammatory mediators of glomerular injury and mechanisms of activation of autoreactive T cells. (1994) (7)
Haemolytic Uraemic Syndromes (1984) (7)
Blood cyclosporine level soon after kidney transplantation is a major determinant of rejection: insights from the Mycophenolate Steroid-Sparing Trial. (2005) (7)
Autotaxin Inhibitor Protects from Chronic Allograft Injury in Rat Kidney Allotransplantation (2019) (7)
The hemolytic uremic syndrome. (1985) (7)
Studies of privileged sites and organ transplantation. (1993) (7)
Recent developments in the management of membranous nephropathy. (1997) (7)
Cyclosporine/tacrolimus (FK-506) (1998) (7)
Renin-angiotensin system and glomerular prostaglandins in early nephrotoxicity of ciclosporin. (1986) (7)
ADAMTS13 Deficiency Shortens the Life Span of Mice With Experimental Diabetes (2018) (7)
Development of a mass spectrometric method to quantitate platelet activating factor in mouse urine. (1989) (7)
Prostacyclin and renal diseases. (1982) (7)
Mesenchymal Stromal Cell Therapy in Solid Organ Transplantation (2021) (7)
Abnormalities in arachidonic acid metabolites in nephrotoxic glomerular injury. (1989) (7)
Invited letter in response to: “Is the kidney donor profile index (KDPI) universal or UNOS‐specific?” (2018) (7)
Tacrolimus and ciclosporin microemulsion in renal transplantation (2002) (7)
Role of ultrastructural determinants of glomerular permeability in ultrafiltration function loss. (2020) (7)
Membranoproliferative glomerulonephritis: no longer the same disease and may need very different treatment. (2021) (7)
Title: Chronic Kidney Disease of Uncertain Aetiology; Prevalence and Causative Factors in a Developing Country (7)
Mesenchymal Stromal Cells for AKI after Cardiac Surgery. (2017) (7)
Molecular Studies and an ex vivo Complement Assay on Endothelium Highlight the Genetic Complexity of Atypical Hemolytic Uremic Syndrome: The Case of a Pedigree With a Null CD46 Variant (2020) (7)
IgA nephropathy: a stem cell disease? (1999) (7)
Studies by conventional and “low denaturing” isoelectric focusing on albumin microheterogeneity under normal conditions and in experimental nephrosis (1987) (7)
Investigational drugs for diabetic nephropathy (2008) (7)
Myasthenia gravis, thrombocytopenia and HLA antigens. (1977) (7)
Vascular factors in the pathogenesis of uraemic bleeding. (1978) (7)
Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome. (2004) (6)
Terminal complement effectors in atypical hemolytic uremic syndrome: C5a, C5b-9, or a bit of both? (2019) (6)
The role of eicosanoids in the pathogenesis of hemolytic uremic syndrome. (1994) (6)
Excess total mortality in 2021 in Italy was about one third of that observed in 2020 (2021) (6)
Fresh lemon juice supplementation for the prevention of recurrent stones in calcium oxalate nephrolithiasis: A pragmatic, prospective, randomised, open, blinded endpoint (PROBE) trial (2021) (6)
Vascular prostacyclin and plasminogen activator activity in experimental and clinical conditions of disturbed haemostasis or thrombosis. (1979) (6)
Inhibition of the renin-angiotensin system and cardio-renal protection: focus on losartan and angiotensin receptor blockade (2005) (6)
Clinical Management of Chronic Kidney Disease Patients in Italy: Results from the IRIDE Study (2018) (6)
Possible Role of HLA-B8 Antigen as a Genetic Marker of Autoimmune Thrombocytopenia in a Patient with Myasthenia Gravis (1977) (6)
Proteins abnormally filtered throughout glomerular capillary have an intrinsic renal toxicity. (1996) (6)
Insights into the Effects of Complement Factor H on the Assembly and Decay of the Alternative Pathway C3 Proconvertase and C3 Convertase* (2016) (6)
Comment on: Robertson (2010) Islet Transplantation a Decade Later and Strategies for Filling a Half-Full Glass. Diabetes;59:1285–1291 (2010) (6)
Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial (2017) (6)
Kidney prevention recipes for your office practice. (2005) (6)
Can we really lessen kidney damage to the point that the loss of renal function of progressive nephropathy may revert? (2003) (6)
A preclinical overview of emerging therapeutic targets for glomerular diseases (2019) (6)
Therapeutic use of HMG-CoA reductase inhibitors: current practice and future perspectives (2004) (6)
Should We Still Believe in Randomized Controlled Trials in Nephrology? (2016) (6)
The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019 (2022) (6)
Metabolism of thromboxane B2 in the isolated perfused rat kidney: mass spectrometric identification of urinary products. (1989) (6)
Evidence for a role of nitric oxide in hypertension and in renal disease in man. (1996) (6)
The establishment and validation of novel therapeutic targets to retard progression of chronic kidney disease. (2017) (6)
Interleukin-1 and glomerular mesangial cells. (1993) (6)
Conflict of interest as seen from a researcher’s perspective (2002) (6)
DOES ASPIRIN PRECIPITATE MAJOR GASTROINTESTINAL BLEEDING IN PATIENTS ON HÆMODIALYSIS? (1977) (6)
Bleeding Time in Uremia (1996) (6)
FC 036IPTACOPAN (LNP023): A NOVEL ORAL COMPLEMENT ALTERNATIVE PATHWAY FACTOR B INHIBITOR SAFELY AND EFFECTIVELY STABILISES EGFR IN C3 GLOMERULOPATHY (2021) (6)
The scientific care for prevention: an overview. (2005) (6)
Mechanisms of progression of chronic renal disease. (2002) (6)
The possible role of endothelin in the process of progressive renal deterioration in experimental and human glomerulopathies. (1993) (6)
In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS 13 in thrombotic thrombocytopenic purpura (2018) (6)
Excess mortality in Italy in 2020 by sex and age groups accounting for demographic changes and temporal trends in mortality. (2021) (5)
Familial and recurrent forms of hemolytic uremic syndrome/thrombotic thrombocytopenic purpura. (2001) (5)
Mycophenolic Acid Formulation Affects Cyclosporine Pharmacokinetics in Stable Kidney Transplant Recipients (2006) (5)
Chronic renal disease (2001) (5)
Challenges in Understanding Acute Postinfectious Glomerulonephritis: Are Anti-Factor B Autoantibodies the Answer? (2020) (5)
ASPHYXIA IN GOODPASTURE'S SYNDROME: EARLY TREATMENT BY IMMUNOSUPPRESSION AND PLASMA EXCHANGE (1978) (5)
Kidney/pancreas transplantation (1994) (5)
Abnormalities of arachidonate metabolism in experimental ciclosporin nephrotoxicity. (1989) (5)
Mycophenolate mofetil versus azathioprine in kidney transplant recipients on steroid-free, low-dose cyclosporine immunosuppression (ATHENA): A pragmatic randomized trial (2021) (5)
Antiplatelet agents: effects on the progressive renal disease. (1991) (5)
Idiopathic membranous nephropathy (1993) (5)
Haemostasis and the Kidney (1989) (5)
Failure of prostacyclin to improve peripheral arterial disease in dialysis patients. (1990) (5)
Low Mortality and Key Aspects of Delivery of Care for End-Stage Renal Disease in Italy (2009) (5)
β-cell transplantation for diabetes therapy – Authors' reply (2008) (5)
Atypical hemolytic uremic syndrome associated with a factor B genetic variant and fluid-phase complement activation: an exception to the rule? (2020) (5)
RAS blockade: Nephroprotection by dual RAS blockade—a welcome back (2015) (5)
New strategies to prevent cardiovascular risk in chronic kidney disease. (2008) (5)
EGF receptor–mediated FUS phosphorylation promotes its nuclear translocation and fibrotic signaling (2020) (5)
Renoprotective Therapy in Patients With Nondiabetic Nephropathies (2012) (5)
Genetics of rare diseases of the kidney: learning from mouse models (2004) (5)
Ethical disputes still beset Italian medicine 150 years after Count Cavour's death (2012) (5)
Effect of Seliciclib (CYC202, R-Roscovitine) on Lymphocyte Alloreactivity and Acute Kidney Allograft Rejection in Rat (2008) (5)
Steroids and cytotoxic drugs in the treatment of membranous glomerulopathy. (1988) (5)
Intrathymic transplantation of donor cells allows a stabilized, incompatible renal transplant to survive indefinitely after cyclosporine withdrawal. (1993) (5)
Insights into the effects of complement factor H on the assembly and decay of the alternative pathway C3 proconvertase and C3 convertase. (2017) (5)
Angiotensin-converting enzyme 2: from a vasoactive peptide to the gatekeeper of a global pandemic (2020) (5)
Plasma manipulation in hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. (1992) (5)
Platelet and vascular prostaglandins in uraemia, thrombotic microangiopathy and pre-eclampsia. (1981) (5)
Autologous Stem Cell and Kidney Transplantation for Primary Amyloidosis Associated with ESRD: Which Should Come First? (2005) (5)
Recent advances in immunosuppression and acquired immune tolerance in renal transplants. (2016) (5)
Low‐dose aspirin and bleeding in uremia (1993) (5)
CRISPR-Cas9-Mediated Correction of the G189R-PAX2 Mutation in Induced Pluripotent Stem Cells from a Patient with Focal Segmental Glomerulosclerosis. (2019) (4)
Treatment of thrombotic microangiopathy (1995) (4)
Effect of hemodynamic conditions on arteriovenous fistula for hemodialysis access. (2002) (4)
Sirtuin 3 in acute kidney injury (2015) (4)
Dual RAS blockade—controversy resolved (2013) (4)
Omega-3 polyunsaturated fatty acids affect sirolimus exposure in kidney transplant recipients on calcineurin inhibitor-free regimen. (2010) (4)
Basiliximab (2020) (4)
Assessment of glomerular size-selective function with fractional clearance of neutral dextran. (1998) (4)
The impact of COVID-19 on total mortality in Italy up to November 2020. (2021) (4)
Two-hour post dose cyclosporine monitoring does not fit all in kidney transplantation (2005) (4)
The Glomerulus: Mechanisms and Patterns of Injury (2014) (4)
Post-translational modifications by SIRT3 de-2-hydroxyisobutyrylase activity regulate glycolysis and enable nephrogenesis (2021) (4)
Neuropeptide Y as a risk factor for cardiorenal disease and cognitive dysfunction in chronic kidney disease: translational opportunities and challenges (2021) (4)
Long-Term Kidney and Systemic Effects Of Calorie Restriction in Overweight or Obese Type 2 Diabetic Patients (C.Re.S.O. 2 Randomized Controlled Trial). (2022) (4)
Glomerulonephritis: from new knowledge on the mechanisms of tissue damage to novel therapies (1995) (4)
Immunotolerance: from new knowledge of mechanisms of self-tolerance to future perspectives for induction of renal transplant tolerance. (1995) (4)
Author Correction: Estimated GFR: time for a critical appraisal (2018) (4)
Preventing microalbuminuria with benazepril, valsartan, and benazepril–valsartan combination therapy in diabetic patients with high-normal albuminuria: A prospective, randomized, open-label, blinded endpoint (PROBE) study (2021) (4)
Reduced fibrinolytic activity in glomeruli isolated from rabbits infused with tumor necrosis factor. (1993) (4)
Renin–angiotensin system: Meta-analyses can misdirect decisions on treatment (2013) (4)
Albuminuria as a risk factor for mild cognitive impairment and dementia—what is the evidence? (2021) (4)
Treatment of chronic proteinuric kidney disease: what next? (2009) (4)
Erratum: 17β-estradiol corrects hemostasis in uremic rats by limiting vascular expression of nitric oxide synthases (American Journal of Physiology (October 2000) 279 (F626-F635)) (2001) (4)
Optimizing Allocation of Kidneys from Older Donors (2011) (4)
Candesartan and renal protection: more than blocking angiotensin type 1 receptor? (2008) (4)
Halting the progression of renal disease: where we stand? (2002) (4)
New biologics in the treatment of rare glomerular diseases of childhood (2017) (4)
Comparison of exposure response relationship of atrasentan between North American and Asian populations (2017) (4)
Thrombotic microangiopathies. (1991) (4)
Varying patterns of the antihypertensive and antialbuminuric response to higher doses of renin–angiotensin–aldosterone system blockade in albuminuric hypertensive type 2 diabetes mellitus patients (2011) (4)
Induction of unresponsiveness via intrathymic inoculation (1991) (4)
Lymphocyte depletion for kidney transplantation: back to the past? (2008) (4)
STAGNATIONS AND REGRESSIONS IN THE TREATMENT OF PRIMARY GLOMERULONEPHRITIS (1983) (4)
Haemolytic uraemic syndrome: report of a case and new pathogenetic concepts. (1980) (4)
Renal cyclophilin-like protein gene expression parallels changes in sodium excretion in experimental nephrosis and is positively modulated by atrial natriuretic peptide. (1993) (4)
Pathogenesis of Preeclampsia (1986) (4)
Prevalence and significance of hypertension in systemic lupus erythematosus. (1993) (4)
Islet transplantation: need for a time-out? (2008) (4)
The Girl with the Curl (1995) (4)
Update on mesenchymal stromal cell studies in organ transplant recipients. (2019) (4)
Hemolytic uremic syndrome associated with verocytotoxin-producing Escherichia coli infection in acquired immunodeficiency syndrome. (1990) (4)
Xenotransplantation: a challenge for the future of transplant medicine. (1998) (4)
Does remission of renal disease associated with antihypertensive treatment exist? (2007) (3)
ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy. (1999) (3)
Molecular basis of familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. (2003) (3)
More on renal disease progression: is interstitial inflammation truly protective? (2007) (3)
Proteinuria and Tubulotoxicity (2018) (3)
Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomes (2021) (3)
Angiotensin-converting enzyme inhibition or angiotensin receptor blockade in hypertensive diabetics? (2003) (3)
Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial (2017) (3)
Chapter 87 – Role of Proteinuria in the Progression of Renal Disease (2013) (3)
Let's assume that hepatitis C reduces the cardiovascular risk in dialysis patients: are there practical implications? (2006) (3)
Data on the assessment of LV mechanics by speckle tracking echocardiography in ADPKD patients (2018) (3)
The kidney triggers graft-versus-host disease in experimental combined transplantation of kidney and stem cell-enriched peripheral leukocytes. (1996) (3)
Nephropathy in NIDDM Patients, Predictors of Outcome (2000) (3)
Erratum: Building a network of ADPKD reference centres across Europe: the EuroCYST initiative(Nephrology Dialysis Transplantation) (2014) 29 :suppl 4 (iv26-iv32) doi: 10.1093/ndt/gfu091) (2014) (3)
Estimated Lifetime Benefit of Combined RAAS and SGLT2 Inhibitor Therapy in Patients with Albuminuric CKD without Diabetes (2022) (3)
CYCLOSPORIN A (CyA) INDUCED ENDOTHELIAL CELL INJURY (1987) (3)
Association of CFHR1 homozygous deletion with acute myelogenous leukemia in the European population (2016) (3)
High serum cholesterol: a missed risk factor for chronic kidney disease mortality. (2014) (3)
Stamina therapies: Time to call a halt (2014) (3)
Platelets from Uraemic Patients React Normally to Prostacyclin (1980) (3)
Dearing—a report to be embraced (1997) (3)
[The role of endothelin in the progression of the renal disease in an experimental model of chronic kidney failure]. (1993) (3)
Disease of the Month Hemolytic Uremic Syndrome (2005) (3)
Low-Dose RATG with or without Basiliximab in Renal Transplantation: A Matched-Cohort Observational Study (2015) (3)
[Drugs for rare diseases: the blessing of being orphans.] (2019) (3)
Reply to ‘Strengths and limitations of estimated and measured GFR’ (2019) (3)
Clinical trials: ISN–ACCTS: global initiatives to improve clinical research (2014) (3)
Human iPSC-derived neural crest stem cells can produce EPO and induce erythropoiesis in anemic mice. (2021) (3)
Tertatolol ameliorates renal function in rats with chronic renal failure. (1988) (3)
Epidemiology and outcome - 2 (2009) (3)
Bone Marrow Mesenchymal Stem Cells in Organ Repair and Strategies to Optimize their Efficacy (2011) (3)
Preimplantation Histological Score Associates with 6-Month GFR in Recipients of Perfused, Older Kidney Grafts: Results from a Pilot Study (2021) (3)
Role of thymic- and graft-dependent mechanisms in tolerance induction to rat kidney transplant by donor PBMC infusion. (2007) (3)
Abstract 426: The Diovan Reduction Of Proteinutria (Drop) Study: Albuminuria Response to High-Doses Of Valsartan in Type 2 Diabetes Mellitus (2006) (3)
Role of eicosanoids as mediators of glomerular injury in immune-mediated nephropathies. (1989) (3)
Humoral immunity in kidney transplantation: what clinicians need to know. Preface. (2008) (3)
Renal involvement in sarcoidosis: histological patterns and prognosis, an Italian survey (2021) (3)
Effect of a Novel Immunosuppressant, ST1959, on the Immune System and Renal Allograft Survival in Rats (2005) (3)
Genes and molecular medicine in the future of organ transplantation (1999) (3)
Characterization of a Rat Model of Myeloperoxidase-Anti-Neutrophil Cytoplasmic Antibody-Associated Crescentic Glomerulonephritis (2021) (3)
Kidney failure stabilizes after an increase over 2 decades. (2007) (3)
Sirtuin 3 Deficiency Aggravates Kidney Disease in Response to High-Fat Diet through Lipotoxicity-Induced Mitochondrial Damage (2022) (3)
Mutations of factor H (HF) in familial Hemolytic Uremic Syndrome (HUS) / Thrombotic Thrombocytopenic Purpura (TTP) (2000) (2)
ADP, Ristocetin, Bovine Factor VIII and Thrombasthenic Platelets (1976) (2)
Drugs for the prevention and treatment of COVID-19 and its complications: An update on what we learned in the past 2 years (2022) (2)
Diverse Functional Implications of ADAMTS13 Gene Mutations in Patients with TTP and Congenital Deficiency. (2004) (2)
Interplay between Diagnostic Criteria and Prognostic Accuracy in Chronic Kidney Disease (2016) (2)
Proteinuria and glomerulosclerosis. New clues from experimental models. (1987) (2)
Platelet and vascular prostaglandins in uremia (1981) (2)
Section Review Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis: New antirejection drugs (1996) (2)
Introduction to Focus on Fabry nephropathy: biomarkers, progression, and disease severity. (2010) (2)
Nitric oxide and renal perfusion in humans. (2002) (2)
Glomerular hypertrophy and progression: Summary and concluding remarks (1994) (2)
Medicine and art: one culture? (2009) (2)
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial (2023) (2)
MO106: Circulating Neutrophil Count is Associated with Severity of Chronic Kidney Disease (2022) (2)
Current Status of Islet Transplantation (2014) (2)
Sustained efficacy and safety of eculizumab in patients with atypical hemolytic uremic syndrome with long disease duration and chronic kidney disease: 3-year update (2015) (2)
In search of an ideal drug for safer treatment of obesity: The false promise of pseudoephedrine (2021) (2)
Mesenchymal Stem Cells in Solid Organ Transplantation (MiSOT) Fourth Meeting (2013) (2)
Coagulation Problems in Dialysis Patients (2000) (2)
Five years survival on hemodialysis predicted by artificial neural network model (2010) (2)
CHAPTER 89 – Role of Proteinuria in Progression (2008) (2)
Abdominal pain and acute nephritis in a man with a recent renal transplant. (1998) (2)
No excess mortality among working-age Italians during the Omicron wave of Covid-19. (2022) (2)
Haemolytic—Uraemic Syndrome and Thrombotic Thrombocytopenic Purpura (1993) (2)
Experimental pathology - 2 (2009) (2)
Progressive decrease of the healthcare impact of the post‐COVID condition after the first disease wave in Lombardy, Italy (2022) (2)
Hemolytic Uremic Syndrome in an Infant with Primary Hyperoxaluria Type II: An Unreported Clinical Association (2019) (2)
The Onset and Resolution of Renal Fibrosis: A Human Perspective (2016) (2)
Prostacyclin and Hemolytic Uremic Syndrome: From the Laboratory to An International Registry (1987) (2)
Assessment of in vitro differentiation of bovine pancreatic tissue in insulin-expressing cells. (2008) (2)
[Functional loss of the transplanted kidney: immunological and non-immunological factors]. (2004) (2)
Transplant tolerance: facts and future. (1999) (2)
Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies (2022) (2)
SaO006INCREASED PRE-GLOMERULAR RESISTANCE AND KIDNEY HYPOPERFUSION MAY SUSTAIN ACCELERATED GFR DECLINE IN HYPERTENSIVE, TYPE 2 DIABETICS WITH NORMAL AND HIGH NORMAL ALBUMINURIA (2018) (2)
Antihypertensive therapy in chronic renal disease: a place for sympathicolytic agents? (2003) (2)
Recellularization of Kidney Scaffold With Stem Cells (2017) (2)
Albuminuria Regression in Diabetes: A Therapeutic Target for Nephro- and Cardio-Protection, in Clinics and Research (2019) (2)
Fast Track Complement Factor H Mutation in Familial Thrombotic Thrombocytopenic Purpura with ADAMTS 13 Deficiency and Renal Involvement (2005) (2)
COVID-19 and the Kidney: Should Nephrologists Care about COVID-19 rather than Maintaining Their Focus on Renal Patients? (2021) (2)
MO126CLINICAL AND BIOMARKER CHARACTERISTICS OF PATIENTS WITH C3G OR IC-MPGN ENROLLED IN TWO PHASE II STUDIES INVESTIGATING THE FACTOR D INHIBITOR DANICOPAN* (2021) (2)
Case Report: Effects of Anti-SARS-CoV-2 Convalescent Antibodies Obtained With Double Filtration Plasmapheresis (2021) (2)
presentation, response to treatment, and outcome Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical (2013) (2)
Thrombogenesis and Anticoagulation in Patients Undergoing Chronic Hemodialysis (1996) (2)
Innovative strategies for pharmacological intervention in immune damage to the kidney. (1995) (2)
The regenerative potential of stem cells in acute renal failure. (2006) (2)
Low-protein diet prevents glomerular damage in experimental nephrosis. (1988) (2)
Humoral Immunity in Kidney Trasplantation: What Clinicians Need to Know (2008) (2)
QTc prolongation: methadone's effi cacy-safety paradox (2006) (2)
Conversion from Brand-Name Neoral to the Generic Ciqorin in Stable Renal Transplant Recipients (2016) (2)
[Strategies for a greater supply of organs for transplantation]. (2001) (2)
Bleeding and Hemostasis in Acute Renal Failure (2019) (2)
alpha 1-Antitrypsin therapy in a case of thrombotic thrombocytopenic purpura. (1995) (2)
The Bergamo Kidney Transplant Program. (2005) (2)
17beta-estradiol corrects hemostasis in uremic rats by limiting vascular expression of nitric oxide synthases. (2000) (2)
Optimization of cyclosporine therapy in kidney transplantation. (1998) (2)
Glomerular diseases in pregnancy: pragmatic recommendations for clinical management. (2022) (2)
Thrombotic microangiopathies in the intensive care unit: many questions, some answers. (2001) (2)
The Lancet Kidney Campaign: an opportunity for partnerships (2016) (2)
Thrombospondin secretion by glomerular mesangial cells in culture is regulated by cytokines and growth factors (1993) (2)
SARS-CoV-2 Spike Protein 1 Activates Microvascular Endothelial Cells and Complement System Leading to Thrombus Formation (2021) (2)
Vascular endothelin and renal disease progression. (1992) (2)
Morphofunctional Effects of C5 Convertase Blockade in Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Report of Two Cases with Evidence of Terminal Complement Activation (2020) (2)
Deficiency of ADAMTS‐13 in thrombotic and thrombocytopenic purpura (2003) (2)
HAMORRHAGISCHE DIATHESE BEI CHRONISCHER URAMIE (1984) (2)
POS-045 Evaluating BCX9930, an Oral Factor D Inhibitor for Treatment of Complement-Mediated Kidney Disease: A Proof-of-Concept Study (RENEW) (2022) (2)
Cells for treating organ damage: how long will we need them? (2011) (1)
Induction of unresponsiveness via intrathymic inoculation (1991) (1)
The role of the endothelium in thrombotic thrombocytopaenic purpura and haemolytic uraemic syndrome (1995) (1)
How should patients with, or at risk of, cardiovascular disease be screened for chronic kidney disease? (2007) (1)
Effects of Octreotide–Long-Acting Release Added-on Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease: Pilot, Randomized, Placebo-Controlled, Cross-Over Trial (2023) (1)
Angiotensin-receptor blockers for renal protection in Type 2 diabetes (2006) (1)
Nephrology. Reducing mortality and increasing awareness. (1998) (1)
Pharmacogenetics and pharmacogenomics of immunosuppressive agents: perspective for individualized therapy. (2004) (1)
Generation of Regulatory T Cells Semiallogeneic Heart Transplant through the Cells Prolongs the Survival of a Pretransplant Infusion of Mesenchymal Stem (2008) (1)
Amnion epithelial cells are an effective source of factor H and prevent kidney complement deposition in factor H-deficient mice (2021) (1)
Treatment of Bleeding in Dialysis Patient (2009) (1)
The Emerging Nephrologist: A Training Vision (2005) (1)
Cord Blood Mesenchymal Stem Cells for Acute Renal Failure Repair. (2006) (1)
Intensive BP Control in Patients with CKD and Risk for Adverse Outcomes (2023) (1)
PUK12 COST-EFFECTIVENESS OF ACE INHIBITOR THERAPY TO PREVENT DIALYSIS IN NON-DIABETIC NEPHROPATHY—INFLUENCE OF THE ACE INSERTION / DELETION POLYMORPHISM (2009) (1)
STOPping peanut allergy: the saga of food oral immunotherapy (2014) (1)
Italy, the Land of Holy Miracles—revisited (2016) (1)
Eicosanoids and Acute Renal Failure (1990) (1)
Clinical problem solving. The girl with the curl. (1995) (1)
The factor H-aHUS mutation database and website: Update and integration of MCP and FI mutations with structural models (2007) (1)
Functional Magnetic Resonance Imaging Versus Kidney Biopsy to Assess Response to Therapy in Nephrotic Syndrome: A Case Report (2020) (1)
ANTILYMPHOCYTE THERAPY IN KIDNEY TRANSPLANTATION: A PROSPECTIVE RANDOMIZED TRIAL OF FULL-DOSE RABBIT ANTI-HUMAN THYMOCYTE GLOBULIN (RATG) VERSUS LOW-DOSE RATG AND BASILIXIMAB (2004) (1)
Effects of tertatolol on renal function in the isolated perfused rat kidney. (1989) (1)
Exciting times for renal medicine (2010) (1)
Prevalence of C3 mutations in primary membranoproliferative glomerulonephritis (2013) (1)
The role of mTOR inhibition in the control of autosomal dominant polycystic kidney disease (2010) (1)
Neuropeptide Y as a risk factor for cardiorenal disease and cognitive dysfunction in CKD: translational opportunities and challenges (1)
Remission/regression of chronic renal disease: a realistic task for the new generation of nephrologists (2000) (1)
Effect of inborn pancreatic islet deficit in the Munich Wister Frömter rat (2010) (1)
Disorders of hemostasis in dialysis patients (2012) (1)
Chapter 68 – Treatment of Anemia and Bleeding in Chronic Kidney Disease (2008) (1)
Tissue Engineering of Renal Tissue (Kidney) (2017) (1)
Gene therapy to the kidney. (2001) (1)
Diabetic Nephropathy: Present and Future Challenges (2005) (1)
Challenges to achieving clinical transplantation tolerance (2004) (1)
Chapter 26 – Thrombotic Microangiopathies (2008) (1)
Basiliximab: A Viewpoint by Giuseppe Remuzzi (1999) (1)
The kidney transplant program at the Bergamo Center. (2000) (1)
Prevention of Chronic Renal Diseases in the Elderly (2008) (1)
Imaging the Kidney with an Unconventional Scanning Electron Microscopy Technique: Analysis of the Subpodocyte Space in Diabetic Mice (2022) (1)
Interaction between multimeric VWF and complement: A fresh look to the pathophysiology of microvascular thrombosis (2017) (1)
Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor Danicopan (2022) (1)
Clinical Kidney Xenotransplantation: Major Progress but More Work Needs to Be Done (2022) (1)
Glomerular resistances predict long-term GFR decline in type 2 diabetic patients without overt nephropathy: a longitudinal subgroup analysis of the DEMAND trial (2021) (1)
Report of the first World Transplant Congress. (2007) (1)
17 b -Estradiol corrects hemostasis in uremic rats by limiting vascular expression of nitric oxide synthases (2000) (1)
Defective glomerular [3H]lysoPAF metabolism in the autologous phase of rabbit nephrotoxic nephritis. (1993) (1)
Therapeutic Corner Screening for Complement System Abnormalities in Patients with Atypical Hemolytic Uremic Syndrome (2007) (1)
Role of endothelin (ET) in the progression of renal disease (1990) (1)
Pharmacokinetics and renal function after conversion from standard to microemulsion formulation of cyclosporine in stable renal transplant patients. (1998) (1)
Author and Subject Index (1999) (1)
[Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD): Somatostatin analogues and mTOR inhibitors]. (2016) (1)
Ramipril in non-diabetic renal failure (REIN study) (1997) (1)
Position Statement from ADA/AACE/EASD/TES in Response to a Recently Published Letter to the Editor in The Lancet and an Editorial Addressing the Israeli-Palestinian Fighting in Gaza (2015) (1)
Hyperaggregability Of Serotonin-Depleted Platelets To Arachidonic Acid (AA) In SLE And Transplant Recipients (1981) (1)
Prostacyclin and thromboxane and the development of preeclampsia. (2000) (1)
Gene therapy for renal diseases and transplantation (2008) (1)
REIN follow-up trial (1998) (1)
Sexual dimorphic response to rituximab treatment: A longitudinal observational study in a large cohort of patients with primary membranous nephropathy and persistent nephrotic syndrome (2022) (1)
Developing regulatory-compliant eletronic case report forms for clinical trials:the DEMAND trial (2009) (1)
Are "routine" clinical and laboratory examinations of any help in the treatment of chronic hemodialysis patients? (1987) (1)
Case Report: Tackling Complement Hyperactivation With Eculizumab in Atypical Hemolytic Uremic Syndrome Triggered by COVID-19 (2022) (1)
Proteinuria and Glomerulosclerosis (1987) (1)
Reducing mortality and increasing awareness (1998) (1)
Department of Error (2017) (1)
What blood-pressure level provides greatest renoprotection in patients with diabetic nephropathy and hypertension? (2006) (1)
Mechanisms and Consequences of Proteinuria (2011) (1)
Low Nephron Number Induced by Maternal Protein Restriction Is Prevented by Nicotinamide Riboside Supplementation Depending on Sirtuin 3 Activation (2022) (1)
Membranous Nephropathy in IgG4-Related Disease (2015) (1)
Risk Factors for Post-Transplant Recurrence of Steroid Resistant Nephrotic Syndrome (Srns): Results from the Podonet Registry (2015) (1)
Unravelling the molecular mechanisms underlying complement dysregulation by nephritic factors in C3G and IC-MPGN (2018) (1)
Inflammation and glomerular injury (2004) (1)
Severe glomerular epithelial cell damage does not prevent passive Heyman nephritis in rats. (1983) (1)
Vascular access-related thrombotic complications: research hypotheses and therapeutic strategies. (2006) (1)
The Toll-IL-1R Member Tir8 Modulates Post-Transplant Kidney Ischemia/reperfusion Injury By Inhibiting Resident F4/80+CX3CR1+ Cell Expansion.: Abstract# 2126 (2014) (1)
Redefining the Role of Donor Biopsies in the Process of Kidney Graft Assessment (2021) (1)
REIN FOLLOW-UP TRIAL. AUTHORS' REPLY (1998) (1)
Long-Term Outcomes of Kidney Transplants from Older/Marginal Donors: A Cohort Study (2021) (1)
In patients with atypical hemolytic uremic syndrome C5 activation causes loss of endothelial thromboresistance (2011) (1)
[Renal transplantation in Autosomal Dominant Polycystic Kidney Disease (ADPKD)]. (2016) (1)
6th Update on Fabry Disease: Biomarkers, Progression and Treatment Opportunities (2019) (1)
A comparison of metrics and performance characteristics of different search strategies for article retrieval for a systematic review of the global epidemiology of kidney and urinary diseases (2018) (1)
ISN Nexus 2016 Symposia: Translational Immunology in Kidney Disease—The Berlin Roadmap (2016) (1)
Kidney Transplantation From a Donor With Acute Kidney Injury: An Unexpected Outcome (2014) (1)
Octreotide Lar in Patients with Autosomal Dominant Polycystic Kidney Disease: From Bench to A Novel Perspective of Therapy (2022) (1)
Residual Plasmatic Activity of ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura Correlates with Disease Phenotype (2011) (1)
ERA-EDTA Immunonephrology working group. (2010) (1)
Is local complement activation involved in renal damage in patients with atypical haemolytic uraemic syndrome? (2008) (1)
Prednisolone plus chlorambucil preserved renal function in membranous nephropathy (2013) (1)
Aspirin and thrombosis in patients undergoing hemodialysis. (1980) (1)
De novo diabetes in dialysis patients: when diabetes is not diabetic nephropathy (1996) (1)
Platelet Lifespan in Pregnancy Complicated by Pre-Eclampsia (1979) (1)
Methods of cardio-renal protection in non-diabetic chronic nephropathies. (2004) (1)
Subject Index Vol. 162, 2009 (2009) (0)
Contributions to Nephrology: Preface (2008) (0)
Renal Outcome with Eculizumab in Patients with aHUS with Native and Transplanted Kidneys: Pooled Analysis of 100 Patients. (2016) (0)
Contents Vol. 136, 2017 (2017) (0)
Absolute differences between measured and estimated GFR values vs baseline measured GFR. (2012) (0)
Nondiabetic Kidney Disease (2010) (0)
Impact of SARS-CoV-2 Omicron and Delta variants in patients requiring intensive care unit (ICU) admission for COVID-19, Northern Italy, December 2021 to January 2022 (2023) (0)
Platelet Prostaglandin Production in the Nephrotic Syndrome (1983) (0)
The combined effect of dynamic conditioning followed by fluid shear stress on an EC-SMC collagen gel co-culture (2000) (0)
Effect of ticlopidine on the evolution of renal disease in rats with reduced renal mass. (1990) (0)
Non-diabetic nephropathies and ACE inhibition (1999) (0)
Subject Index Vol. 27, 2007 (2007) (0)
Genetic diseases and molecular genetics - 2 (2011) (0)
Candidate genes screening in non-Stx-HUS (2007) (0)
The way to cardio-renal protection in non-diabetic chronic nephropathies (2004) (0)
The way to cardio-renal protection in non-diabetic chronic nephropathies (2004) (0)
Faculty Opinions recommendation of Extended-release niacin or ezetimibe and carotid intima-media thickness. (2009) (0)
Multipotent Mesenchymal Stromal Cell Therapy and Risk of Malignancies (2012) (0)
Trials and Tribulations of New Agents, Novel Biomarkers, and Retarding Renal Progression (2011) (0)
Contents Vol. 57, 2011 (2011) (0)
Contents, Vol. 53, 1989 (1989) (0)
Cavour's death and the political difficulties of Italian medicine – Author's reply (2012) (0)
Engineering the vasculature of decellularized rat kidney scaffolds using human induced pluripotent stem cell-derived endothelial cells (2019) (0)
Reply: Nephrons are generated via a series of committed progenitors. (2014) (0)
Use of a composition comprising an association of an angiotensin II AT1 receptor antagonists and indomethacin for producing a medicament for the treatment of kronischen glomerulonephriten (1999) (0)
Is mycophenolate mofetil better than azathioprine in organ transplantation? (2006) (0)
Present and future of CONNECT: a new and compelling project of modern medicine (2021) (0)
Front & Back Matter (2022) (0)
Renal transplantation - basic research (2009) (0)
Complement factor H (CFH) haploinsufficiency causes spontaneous late onset glomerulonephritis (2011) (0)
The need for a multi-disciplinary reflection about frailty and cognitive impairment in chronic kidney disease (2022) (0)
Faculty of 1000 evaluation for Outcomes of kidney transplantation in HIV-infected recipients. (2010) (0)
Direct podocyte damage leads to in-vivo single nephron albuminuria (1995) (0)
Platelet and Vascular Prostaglandins in Uremia and Thrombotic Microangiopathy (1983) (0)
Dexamethasone prevents platelet-activating factor induced proteinuria in isolated perfused rat kidney (1995) (0)
Why and how did Leonardo happen: the Renaissance context (2019) (0)
Modulation of endothelin receptors in hypertension and renal pathophysiology (1995) (0)
Mechanisms and Mediators of Cyclosporine-Induced Renal Vascular Changes (1991) (0)
Glomerulonephritis (1993) (0)
In type-2 diabetics with abdominal obesity, hyperfiltration is a risk factor for accelerated GFR decline and nephropathy. In this academic, single-center, parallel-group, Prospective, Randomized, Open-label, Blinded Endpoint (PROBE) trial (ClinicalTRials.gov number: NCT01213212), consenting >18-year (2016) (0)
Inhibition Of Interleukin-8 (il-8) Activity Prevents Renal Function Deterioration Due To Ischemia/reperfusion In Syngeneic And Allogeneic Rat Kidney Transplantation. (2004) (0)
CFH and CFHR structural variants in atypical Hemolytic Uremic Syndrome: Prevalence, genomic characterization and impact on outcome (2023) (0)
Shiga Toxin Capture by Endothelium in Response to Fractalkine and CX3CR1 Mediate Leukocyte (2008) (0)
The Vatican–Mario Negri–Lancet Commission on the value of life (2017) (0)
[Von Willebrand factor multimers in systemic scleroderma]. (1989) (0)
Early renin-angiotensin-system intervention is more beneficial than late intervention in delaying end-stage renal disease in type 2 diabetes (2016) (0)
Role of the alternative pathway of complement in ischemia/reperfusion and chronic graft injury in a mouse model of kidney allograft (2012) (0)
Excellent Survival Using Kidney Transplants From Older Donors (0)
Epidemiology and CKD - 2 (2009) (0)
CHAPTER 39 – Thrombotic microangiopathies (2012) (0)
RENAL DEVELOPMENT AND CYSTIC DISEASES (2013) (0)
Epidemiology and CKD - 2 (2009) (0)
Faculty Opinions recommendation of Projected effect of dietary salt reductions on future cardiovascular disease. (2010) (0)
Orphan drugs – Authors' reply (2019) (0)
Contents Vol. 40, 2014 (2015) (0)
cells under physiologic flow conditions Verotoxin-1 promotes leukocyte adhesion to cultured endothelial (2011) (0)
The lupus anticoagulant (41879) (1984) (0)
A mouse model of non-Shiga toxin-associated haemolytic uraemic syndrome. (2007) (0)
Table 1. [Molecular Genetic Testing Used in Atypical Hemolytic-Uremic Syndrome]. (2016) (0)
Each patient entered the study after one week of washout of the previous antihypertensive therapy. (1993) (0)
Assessment of diabetic neuropathy using a multimodal approach: Results of a correlation study - The DEMAND study (2007) (0)
Salty tea intake and hypertension in Mongolia (2009) (0)
Pharmacokinetic study of the new cyclosporine-a formulation (neoral™) in adult ALLO-BMT recipients (2000) (0)
FP049 THE ASSOCIATION OF ENDOTHELIN-1 LEVELS WITH RENAL SURVIVAL IN POLYCYSTIC KIDNEY DISEASE PATIENTS (2018) (0)
Altered Renovascular Endothelial Functions During Nephrotoxicity (1991) (0)
NEPHROPATHY IN TYPE 2 DIABETIC PATIENTS, PREDICTORS OF OUTCOME (2004) (0)
Dreaming of normoglycaemia with fewer diet restrictions. (2014) (0)
Use of a pharmaceutical composition containing, in combination, an antagonist of angiotensin AT1 receptor and ii indomethacin for the treatment of chronic glomerulonephritis (1998) (0)
TMA in Kidney Transplantation. (2023) (0)
ERYTROPOIETIN PREVENTS ISCHEMIA-REPERFUSION INJURY IN A RAT MODEL OF KIDNEY TRANSPLANTATION (2006) (0)
Variations of the angiotensin II type 1 receptor gene are associated with extreme human longevity (2012) (0)
Extracellular vesicles derived from T regulatory cells suppress T cell proliferation and prolong allograft survival (2017) (0)
Losartan reduces the burden of ESRD: public health implications from the RENAAL study for the European Union (2002) (0)
Corrigendum to “Let’s assume that hepatitis C reduces the cardiovascular risk in dialysis patients: Are there practical implications?” [J Hepatol 44 (2006) 837–838] (2006) (0)
Full-dose NSAIDs at the first sign of respiratory infection? – Authors’ reply (2022) (0)
Decreased Nephron Number within Physiologic Ranges Increases Susceptibility to Chronic Renal Diseases Later in Life (2020) (0)
Endothelin and renal disease progression. (1994) (0)
Prevention/remission and regression of chronic renal disease (2000) (0)
Effect of the urotensin receptor antagonist palosuran on albuminuria in hypertensive patients with type 2 diabetic nephropathy: results from the PROLONG proof-of-concept study (2008) (0)
Minimisation of immunosuppression in transplantation – Authors' reply (2007) (0)
Contents Vol. 128, 2014 (2015) (0)
Pediatric liver transplantation for metabolic diseases (2002) (0)
Acute renal failure - basic research (2009) (0)
Tolerance in organ transplantation (1999) (0)
Faculty Opinions recommendation of Discovery of autoantibodies targeting nephrin in minimal change disease supports a novel autoimmune etiology. (2021) (0)
Chronic kidney disease: Staging CKD: can we rely on estimated GFRs? (2011) (0)
Faculty Opinions recommendation of Renal and retinal effects of enalapril and losartan in type 1 diabetes. (2009) (0)
Chapter 14 Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura (2007) (0)
Nephrology Worldwide – A Book Review (2021) (0)
A retrospective analysis on disease onset, number of episodes and final outcome in CFH mutated non-Stx-HUS patients (2007) (0)
The year of the pores (1996) (0)
SAT-148 Determinants of outcomes in pediatric chronic kidney disease [CKD] in a low resource setting (2020) (0)
Double transplant of marginal kidneys. (1999) (0)
Lab methods, progression & risk factors for CKD - 2 (2009) (0)
Insights into Glomerular Filtration and Albuminuria. (2021) (0)
Subject Index Vol. 25, 1999 (1999) (0)
FP050URINARY PEPTIDOME ANALYSIS ALLOWS NON-INVASIVE DIAGNOSIS OF THE RCAD SYNDROME (2018) (0)
Contents Vol. 40, No. 4, 2015 (2015) (0)
Addressing acute kidney injury in critically ill newborn babies. (2017) (0)
Erratum: Correction to Lancet HIV ((2016) 3 (e361–87)(S235230181630087X)(10.1016/S2352-3018(16)30087-X) (2016) (0)
Contents Vol. 85, 2000 (2000) (0)
Efﬁciency of curative and prophylactic treatment with rituximab in ADAMTS13-deﬁcient thrombotic thrombocytopenic purpura: a study of 11 cases (2005) (0)
Ramipril and Cardiovascular Outcomes in Patients on Maintenance Hemodialysis: The ARCADIA Multicenter Randomized Controlled Trial. (2021) (0)
Diffusion magnetic resonance imaging for kidney cyst volume quantification and non-cystic tissue characterisation in ADPKD. (2023) (0)
1 C-Reactive Protein and Risk of End-Stage Renal Disease – Results from TREAT ( Trial to Reduce cardiovascular Events with Aranesp Therapy ) (2016) (0)
The antiproteinuric effect of high-dose ramipril: Still an open question (2003) (0)
Every Fifteen Days Forever? (2022) (0)
Invited Lecture 1:Prevention/remission and regression of chronic renal disease (2000) (0)
SP004INHIBITION OF THE C5A RECEPTOR BY CCX168 MARKEDLY REDUCES THE THROMBOGENIC POTENTIAL OF SERUM FROM PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME (2015) (0)
Editorial The global burden of chronic kidney diseases waits for better renoprotection (2009) (0)
11 cases ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of Efficiency of curative and prophylactic treatment with rituximab in (2013) (0)
Polyacrylonitrile Membrane for Hemodialysis: Long-Term Effect on Primary Hemostasis (1986) (0)
Molecular Medicine in Organ Transplantation: How and When? (2001) (0)
Tacrolimus and ciclosporin microemulsion in renal transplantation. Author's reply (2002) (0)
Book Review Treatment of Primary Glomerulonephritis (Oxford Clinical Nephrology Series.) Edited by Claudio Ponticelli and Richard J. Glassock. 260 pp., illustrated. New York, Oxford University Press, 1997. $110. 0-19-262666-3 (1997) (0)
Therapeutic potential of stromal cells of non-renal or renal origin in experimental chronic kidney disease (2018) (0)
Faculty Opinions recommendation of Clinical benefit of enzyme replacement therapy in Fabry disease. (2007) (0)
Contents Vol. 137, 2017 (2017) (0)
TimeCourseandLocalization ofEndothelin-1 Gene Expression ina ModelofRenalDisease Progression (1997) (0)
Clinical perspectives in the prevention and treatment of chronic nephropathy, including an overview of the DEMAND Study (2007) (0)
Updated estimates of excess total mortality in Italy during the circulation of the BA.2 and BA.4-5 Omicron variants: April-July 2022 (2022) (0)
Faculty Opinions recommendation of Tolvaptan in patients with autosomal dominant polycystic kidney disease. (2012) (0)
Microvascular Thrombosis Exuberant C3a Formation That Triggers Complement by Shiga Toxin Promotes Alternative Pathway Activation of (2011) (0)
Contents Vol. 104, 2006 (2006) (0)
Coichicine Interferes with L-Selectin and Leukocyte Function-Associated Antigen-i Expression on Human I Lymphocytes a nd Inhibits I Cell (1996) (0)
Add-On Cyclic Angiotensin-(1-7) with Cyclophosphamide Arrests Progressive Kidney Disease in Rats with ANCA Associated Glomerulonephritis (2022) (0)
Faculty Opinions recommendation of An Indirect Immunofluorescence Method Facilitates Detection of Thrombospondin Type 1 Domain-Containing 7A-Specific Antibodies in Membranous Nephropathy. (2017) (0)
Two-hour post-dose cyclosporine monitoring does not fit all in kidney transplantation (2016) (0)
Unravelling the Role of PAX2 Mutation in Human Focal Segmental Glomerulosclerosis (2021) (0)
Interleukin-1 3 and Tumor Necrosis Factor-ot Induce Gene Expression and Production of Leukocyte Chemotactic Factors, Colony-stimulating Factors, and Interleukin-6 in Human Mesangial Cells (2007) (0)
Post-COVID condition: dispensation of drugs and diagnostic tests as proxies of healthcare impact (2023) (0)
Primary care in a National Health Service: time for radical reform. (2022) (0)
2 1 Chronic kidney disease 2 (2020) (0)
Maintenance Immunosuppression in Kidney Transplantation (2017) (0)
Epidemiology and CKD - 1 (2009) (0)
CONJUGATED ESTROGENS (CE) TO REDUCE BLEEDING IN UREMICS (1987) (0)
SuO039LONG TERM EFFECTS OF OCTREOTIDE TREATMENT IN ADPKD PATIENTS WITH POLYCYSTIC LIVER DISEASE (A SUB-GROUP ANALYSIS OF THE ALADIN TRIAL) (2015) (0)
A young girl with MPGN/HUS and a heterozygous CFH-mutation (2007) (0)
REIN follow-up trial (multiple letters) [6] (1998) (0)
Contents Vol. 27, 2007 (2007) (0)
Shiga Toxin 2 Triggers C3a-Dependent Glomerular and Tubular Injury through Mitochondrial Dysfunction in Hemolytic Uremic Syndrome (2022) (0)
Table 2. [Selected CFB Pathogenic Variants]. (2016) (0)
Farewell letter of the past editor-in-chief: Editorial (1999) (0)
Hemostasis in renal failure Hämostase bei Nierenversagen (1998) (0)
Altered Regulation Of Prostacyclin (PGI2) Activity In Severe Pre-Eclampsia (1981) (0)
POS-037 ACTIVATION OF THE ALTERNATIVE PATHWAY OF COMPLEMENT FAVORS THROMBUS FORMATION ON MICROVASCULAR ENDOTHELIAL CELLS IN ACUTE HEMOLYTIC UREMIC SYNDROME INDUCED BY SHIGA-LIKE-TOXIN PRODUCING E.COLI (STEC-HUS) (2022) (0)
Faculty Opinions recommendation of Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. (2021) (0)
LITERATURE Watch Implications for transplantation (2013) (0)
Thromboxane synthase inhibition increases urinary protein excretion in diabetic nephropathy (1993) (0)
Abstracts for IPNA Congress in Shanghai, China 2013 (2013) (0)
The hemolytic uremic syndrome. (1985) (0)
POS-001 A NOVEL CFHR5 COPY NUMBER VARIATION ASSOCIATED WITH POST-PARTUM ATYPICAL HUS SUPERIMPOSED TO HELLP SYNDROME (2022) (0)
Genetic rearrangements in CFH and CFH-Related genes in atypical Hemolytic Uremic Syndrome, C3 glomerulopathy and Immuno-Complex mediated MPGN (2017) (0)
[Mechanisms of endothelial damage in thrombotic microangiopathy]. (2003) (0)
aHUS-associated genetic complement abnormalities cause C3 deposition on endothelial cells: Protective effects of specific inhibitors of the alternative pathway of complement (2009) (0)
WCN23-0403 AN OPEN-LABEL, NON-RANDOMIZED EXTENSION STUDY TO EVALUATE LONG-TERM EFFICACY, SAFETY, AND TOLERABILITY OF LNP023 IN SUBJECTS WITH C3 GLOMERULOPATHY: INTERIM ANALYSIS OF PHASE 2 STUDY (2023) (0)
Title Pages / Contents (1999) (0)
The Glomerulus: Mechanisms of Injury (2010) (0)
Front & Back Matter (2022) (0)
MYCOPHENOLIC ACID FORMULATIONS AFFECT CYCLOSPORINE PHARMACOKINETICS IN STABLE KIDNEY TRANSPLANT RECIPIENTS. (2006) (0)
Contents, Vol. 22, 1978 (1973) (0)
Kidney diseases (2021) (0)
Uraemic Bleeding : Contributory Role Of Red Cells (1981) (0)
Proteinuria and glomerular damage (1992) (0)
A platelet-activating factor receptor antagonist protects against renal function deterioration in nephrotoxic nephritis. (1987) (0)
Kidney diseases (2022) (0)
Consultants for the American Journal of Nephrology 2007 (2007) (0)
Early and late scanning electron microscopy findings in diabetic kidney disease (2018) (0)
Cardiovascular & Renal The renoprotective potential of endothelin receptor antagonists (1997) (0)
Donor Age Impairs the Capacity of Human Mesenchymal Stromal Cells to Repair Cardiac and Renal Damage (2016) (0)
Systemic and Renal Response of GAL-KO Pigs To Human Angiotensin II.: Abstract# D2856 (2014) (0)
Analysis by fast atom bombardment mass spectrometry of phospholipids from tubuli, glomeruli, and urine of normal rats and rats with acute renal failure. (1992) (0)
Induction of Tolerance in Allotransplantation (2007) (0)
Cysteine proteinase activity in Thrombotic thrombocytopenic Purpura (TTP) (1992) (0)
Semi-Automated Quantification of Cyst Volume from T2-Weighted MR Images in ADPKD (2008) (0)
Donor Pbmc Induced Tolerance Is Associated With The Emergence Of Anergic T Cells From The Thymus Followed By Generation Of Regulatory T Cells In The Graft. (2004) (0)
The Future of Nephrology and Public Health. (2021) (0)
Subject Index, Vol. 53, 1989 (1989) (0)
Worldwide cardiovascular and ESRD outcomes attributable to reduced GFR Running Title: Reduced GFR-attributed health loss (2018) (0)
Immunophenotypic Alterations in Adult Patients with Steroid-Dependent and Frequently Relapsing Nephrotic Syndrome (2023) (0)
[Thrombotic microangiopathy]. (2003) (0)
Complement (C) activation contributes to microvascular thrombosis in Shiga toxin-associated HUS (2009) (0)
Subject Index Vol. 85, 2000 (2000) (0)
The uses of error: diagnostic preferences (2001) (0)
MYSS: should we alter clinical practice? Authors' reply (2004) (0)
to reduced GFR (2017) (0)
Contents Vol. 25, 1999 (1999) (0)
MDR1 POLYMORPHISMS INFLUENCES DAILY CYCLOSPORINE EXPOSURE IN STABLE KIDNEY TRANSPLANT RECIPIENTS. (2006) (0)
Dendritic Cells (dcs) Genetically Engineered To Block Nf-kb Pathway Induce The Formation Of Potent Type-1-like T Regulatory Cells (treg) (2004) (0)
TransplantsProlong Survival of Semiallogeneic Heart In Vitro Fertilization or Nuclear Transfer, Embryonic Stem Cells, Derived Either after (2011) (0)
Assay for c5b-9 deposition in complement-associated disorders (2017) (0)
Errors in medicine, denunciations, spots, lawyers vs physicians (2014) (0)
(letter) Escherichia coli infection in acquired immunodeficiency syndrome Hemolytic uremic syndrome associated with verocytotoxin-producing (2011) (0)
LIMITED SAMPLING STRATEGIES FOR THE ESTIMATION OF SIROLIMUS EXPOSURE IN KIDNEY TRANSPLANT RECIPIENTS. (2006) (0)
Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease : Data from the TREAT trial (2018) (0)
EFFECT OF INTRAVENOUS IMMUNOGLOBULINS (SANDOGLOBULIN) ON LEUKOCYTE‐ENDOTHELIUM INTERACTION UNDER FLOW CONDITIONS: 639 (1997) (0)
Reply: Nephrons are generated via a series of committed progenitors (2014) (0)
Correction: Are HLA antigens important in the development of alcohol-induced liver disease? (1982) (0)
Links Between Bolivia, Moldova, and Italy for Prevention of Chronic Nephropathies (2005) (0)
Evaluation of Variation in the Performance of GFR Slope as a Surrogate End Point for Kidney Failure in Clinical Trials that Differ by Severity of CKD (2023) (0)
Front & Back Matter (2020) (0)
Immunological reviews: The alternative pathway or amplification loop of complement. (2022) (0)
To the editor : Deficiency of ADAMTS 13 and thrombotic thrombocytopenic purpura (0)
Immunomodulation by intrathymic donor leukocytes in rhesus monkeys (1997) (0)
Structure and Function in ADPKD: Correlation Between GFR and Relative Volume of Hypo-Enhanced Paranchyma from Contrast-Enhanced CT Imaging (2008) (0)
Renal protective effect of ACE inhibition and angiotensin II blockade (1996) (0)
Epidemiology and CKD - 3 (2009) (0)
Renal prostaglandins and hyperfiltration. (1987) (0)
Renal pathophysiology. (1993) (0)
Renal failure J Gary Abuelo Renal failure (1996) (0)
Propionyl-L-carnitine prevents renal ischemia/reperfusion injury in a rat model of syngeneic kidney transplantation (2000) (0)
Models of human renal disease (1990) (0)
Renal pathophysiology. (1994) (0)
Subject Index Vol. 104, 2006 (2006) (0)
Urinary proteome signature of Renal Cysts and Diabetes syndrome in children (2019) (0)
EFFECT OF A NOVEL IMMUNOSUPPRESSANT, ST1959, ON ALLOGENEIC IMMUNE RESPONSE AND RENAL ALLOGRAFT SURVIVAL IN RATS (2004) (0)
Aspirin in Hypertension of Pregnancy (1992) (0)
Low birth weight, nephron number and chronic kidney disease (2022) (0)
Nephrology. The year of the pores. (1996) (0)
Acute Renal Failure in Kidney Transplant Recipients (2019) (0)
MYSS: should we alter clinical practice? (2004) (0)
Effect of inborn pancreatic islet deficit (2010) (0)
Supplementary Material for: Another Piece of the Puzzle of Podocyte B7-1 Expression: Lupus Nephritis (2016) (0)
Faculty Opinions recommendation of Long-term follow-up after tight control of blood pressure in type 2 diabetes. (2008) (0)
Mele-NEJM-2011-appendix (2012) (0)
Renal transplant tolerance: molecular mechanisms of T cell regulation. Introduction. (1993) (0)
Mantovani products Stimulation of prostacyclin synthesis in vascular cells by mononuclear cell (2005) (0)
Treatment of adult hemolytic-uremic syndrome. (2000) (0)
Vasoactive and Inflammatory Substances (2004) (0)
Long-term adaptive response in COVID-19 vaccine recipients and the effect of a booster dose (2023) (0)
[Table, Molecular Genetics]. (2016) (0)
Pharmacologic Monitoring of Immunosuppressive Drugs (2001) (0)
CHAPTER 29 – Prevention and Therapeutic Management of Bleeding in Dialysis Patients (2008) (0)
Front & Back Matter (2014) (0)
Mesenchymal stromal cell-based therapy in kidney diseases and transplantation (2019) (0)
Regulation of High Shear Rate Induced von Willebrand Factor Mediated Platelet Thrombi by ADAMTS-13 . (2004) (0)
C5a/C5aR interaction mediates complement activation and thrombosis on endothelial cells in atypical hemolytic uremic syndrome (aHUS) (2012) (0)
Subject Index Vol. 7, 1999 (1999) (0)
Intensified inhibition of renin-angiotensin system: A way to improve renal protection? (2007) (0)
124Unravelling the pathophysiology of C3G/IC-MPGN and how to predict disease progression and orient therapies (2017) (0)
Target haemoglobin concentrations in chronic kidney disease (2007) (0)
Developmental Approaches to Kidney Regeneration (2017) (0)
Links Between Bolivia, Moldova and Italy for Prevention of Chronic Nephropathies (2005) (0)
Chapter 26 – Prevention and Therapeutic Management of Bleeding in Dialysis Patients (2017) (0)
Pharmacotherapy options for membranous nephropathy (2016) (0)
Supplementary Material for: Low-Dose RATG with or without Basiliximab in Renal Transplantation: A Matched-Cohort Observational Study (2017) (0)
Contents Vol. 105, 2004 (2004) (0)
Author Correction: Mapping local patterns of childhood overweight and wasting in low- and middle-income countries between 2000 and 2017 (2020) (0)
Use of active ingredients in combination for the treatment of complications of diabetes. (2011) (0)
131. Studies on the renal protective effect of angiotensin converting enzyme inhibition in ageing rats (1991) (0)
DISEASE OF THE MONTH (2003) (0)
Protective Effects of Human Nonrenal and Renal Stromal Cells and Their Conditioned Media in a Rat Model of Chronic Kidney Disease (2020) (0)
Development Donor-Specific Anti-HLA Antibody Associates with a High Incidence of De Novo Depletion and Regeneration , Which Anti-Thymocyte Globulin Induces B Cell but Not Basiliximab / Low-Dose Rabbit In Kidney Transplant Patients , Alemtuzumab (2013) (0)
Platelets in Thrombotic and Non-thrombotic Disorders: Platelets and renal diseases (2002) (0)
Initial combination therapy for treatment of hypertension (2011) (0)
A Putative Role of NO and Oxidant Injury in the Pathogenesis of Hemolytic Uremic Syndrome (1997) (0)
Human mesenchymal stromal cells transplanted into mice stimulate renal tubular cells and enhance mitochondrial function (2017) (0)
[Considerations on clinical drug research in Italy]. (2006) (0)
[Hemolytic uremic syndrome]. (2005) (0)
Diabetes mellitus - basic research (2009) (0)
Amnion epithelial cells are an effective source of factor H and prevent kidney complement deposition in factor H-deficient mice (2021) (0)
Mechanisms of progression of renal disease and possible sites of action of n-3 fatty acids. (1993) (0)
Results for C3 and CFB genetic screening in atypical-HUS (2008) (0)
Rare but Relevant Kidney Disorders (2009) (0)
10th Annual Meeting of the European Renal Cell Study Group (1998) (0)
Highlight from International Congress (2006) (0)
Author Index to Abstracts (1998) (0)
COVID-19 from a pharmacological perspective (2021) (0)
Table 3. [Selected CFH Pathogenic Variants]. (2016) (0)
AAV9-mediated engineering of autotransplanted kidney of non-human primates (2017) (0)
Prostanoid-Related Platelet Abnormalities in Renal Disease (1984) (0)
An ex vivo test to investigate genetic factors conferring susceptibility to atypical haemolytic uremic syndrome (2023) (0)
Manipulating Sirtuin 3 pathway ameliorates renal damage in experimental diabetes (2020) (0)
Absence of Fibroblast-Induced Fibrin Clot Retraction in a Patient with Glanzmann’s Thrombasthenia and Abnormal Wound Healing (1977) (0)
Editorial: Insights in renal pharmacology: 2021 (2022) (0)
Therapeutic Small Interfering RNA Targeting Complement C3 in a Mouse Model of C3 Glomerulopathy (2022) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Giuseppe Remuzzi?

Giuseppe Remuzzi is affiliated with the following schools: